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Abstract
Miconazole and clotrimazole are environmentally-persistent drugs that are entrained into crop soils
through the application of biosolids. There is concern that environmental exposure to such azole
antifungals, which inhibit fungal growth by disrupting the production of the fungal cell membrane
component ergosterol, promotes resistance in clinically or agriculturally relevant fungi. Thus,
either environmentally-relevant or excessive levels of these drugs were applied to microplots over
ten years and compared with drug-free plots. Overall, ergosterol quantification, plates counts, and
identification of >250 fungal isolates showed lower fungal counts and species richness in plots
receiving excessive drug amounts. In addition, fungi from treated plots did not show increased
resistance to a panel of medical and agricultural azole drugs in disk diffusion assays. Altogether,
while the highly contaminated soils showed lower fungal counts, lower species richness, and fewer
isolates highly-susceptible to miconazole, increased resistance to azoles was not evident at
environmentally relevant concentrations.

Keywords: Antifungal resistance, mycology, fungal community diversity, fungal infections,
biosolids, wastewater contaminants
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Summary for Lay Audience
Products sold to treat fungal infections –such as those of the hair, skin, nails, and urogenital tract–
include drugs that specifically kill or slow the growth of fungi. These products tend to be washed
down the shower, sink, or toilet and make their way into the sewage system. Following sewage
treatment, some traces of drugs remain, and two medical antifungal drugs that particularly
accumulate and persist in the environment, possibly due to their use in over-the-counter products,
are clotrimazole and miconazole. Although not used to treat systemic infections, these drugs,
which are chemically defined as azoles, are chemically related to azoles used to treat lifethreatening, systemic fungal infections and agricultural azoles used to control crop diseases in
agriculture. This reliance on azole products has raised concerns over azole contamination of the
environment, resulting from the application of biosolid fertilizer derived from sewage treatment
products onto soils. More specifically, there is concern that azole contamination of soils can shift
the soil fungal community's population structure and lead to the selection of azole-resistant
phenotypes.

To address these concerns, from 2010 to 2020, amounts of clotrimazole and miconazole typical to
those found in biosolid fertilizer were annually added to 2 m2 plots of soil grown with soybeans.
Soil from these microplots, in addition to identical microplots receiving no drugs, were sampled,
starting in 2018, for fungal isolation. The resulting fungal libraries were analyzed for changes in
composition between the control and treated microplots. In addition, fungal libraries from the
treated plots were compared to libraries from the control plots for their susceptibility to
clotrimazole, miconazole, medical azoles used for systemic infections, and agricultural azoles used
for crop protection.

Overall, it was found that the azole-treated soils showed lower fungal counts compared to the
untreated soils and the soils treated with excess clotrimazole and miconazole showed lower species
richness. On the other hand, there was no clear evidence that the fungal community recovered from
the azole-contaminated soils were less susceptible to azoles than fungi recovered from the control
plots. Nonetheless, several species with medical and agricultural significance were recovered from
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the contaminated soils, highlighting the importance of monitoring soil fungi for increased azole
resistance.
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Introduction and Literature review

1.1 History and use of antifungal agents
Although the practice of treating microbial infections with biological preparations dates back to
ancient cultures, German physician Paul Ehrlich kickstarted research into the synthesis of
antimicrobial compounds derived from dyes in the early 1900s. However, possibly due to the
relative rarity of fungal infections prior to the HIV/AIDS epidemic and lack of fungal targets that
are not shared with humans, the development of antifungals lagged behind the development of
antibacterials (Larkin et al., 2019). Nonetheless, ergosterol, an essential fungal cell wall
component not found in human cells, was found to be a suitable molecular target for the polyene
and azole classes of antifungal drugs (Dixon & Walsh, 1996). Thus, during the 1940’s to 1950’s,
treatment for fungal infections transitioned from relying on physical interventions, such as
radiation therapy, and repurposed medications, such as potassium iodide and sulfonamide
antibiotics, to pharmaceuticals designed for a fungal-specific mode of action (Larkin et al., 2019).

The polyene drugs are defined by macrocyclic rings containing polyene structures, which consist
of multiple alternating single carbon-carbon and double carbon-carbon bonds, and are
amphiphilic, meaning that they have hydrophilic and hydrophobic regions. These drugs primarily
work by binding to ergosterol on the fungal cell surface, which results in the formation of pores
through which cytoplasmic contents can leak through (Dixon & Walsh, 1996). Nystatin and
amphotericin B, both isolated from Streptomyces species in 1950 and 1955, respectively, entered
clinical use in the late 1950’s (Larkin et al., 2019).

Subsequently, the azole drugs clotrimazole, miconazole, and econazole were developed and
entered the market from the late 1960’s to the early 1970’s (Larkin et al., 2019). Azole drugs bind
to and inhibit the enzyme lanosterol 14 α-demethylase (CYP51A1), which catalyzes the
demethylation of lanosterol to ergosterol (Dixon & Walsh, 1996). Effects of this disruption include
reduced membrane fluidity due to the absence of ergosterol, the build-up of toxic 14α-methylsterol
by-products, and, possibly, an increase in saturated fatty acid content in the membrane leading to
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further reduced membrane fluidity (Dixon & Walsh, 1996; Larkin et al., 2019). In addition, at
higher concentrations than those that produce effects via CYP51A disruption, azole drugs have an
immediately lethal effect through direct membrane damage to both eukaryotic and prokaryotic
cells (Van den Bossche et al., 1983). Chemically, azoles are compounds defined by a fivemembered ring containing two nitrogen atoms for imidazoles, or three nitrogen atoms for triazoles
(Dixon & Walsh, 1996).

It has been estimated that while infectious diseases were the cause of one death per thousand deaths
in the pre-antibiotic era of the 1940’s, the age-standardized rate dropped to 0.1 per thousand in the
1970’s due to widespread adoption of antibiotics (Griffiths & Brock, 2003). While the societal
benefit of antifungal drugs has been less quantified than those of antibacterial drugs, the
development of antifungal drugs has undoubtedly reduced the mortality rate associated with
immunodeficiency and reduced the burden of dermatological fungal infections. For example, in a
model of 40-year old patients with acute myeloid leukemia, it was estimated that prophylactic
fluconazole administration approximately halved the probability of developing a fungal infection,
from 0.157 to 0.076, and also slightly reduced the probability of dying from the infection, from
0.285 to 0.238, for an overall increased life expectancy of 0.9 years (Nomura et al., 2006).

1.2 Clinical, community, and agricultural use of antifungals
As of 2019, the World Health Organization List of Essential Medicines includes the imidazoles
clotrimazole and miconazole (Figure 1), which are suitable for oral and topical use, and the secondgeneration triazoles fluconazole, itraconazole, and voriconazole (Figure 2), which are suitable for
intravenous use (World Health Organization, 2019). In addition, the polyenes, nystatin and
amphotericin B, and squalene monooxygenase inhibitors, such as terbinafine, are included (World
Health Organization, 2019). Other effective antimycotic agents on the list include inorganic
compounds, such as selenium sulfide and sodium thiosulfate, and small molecules that inhibit
intracellular fungal targets, such as griseofulvin and flucytosine, which inhibit tubulin and
thymidylate synthase, respectively (World Health Organization, 2019).

3

A

B

Figure 1 – Structures of select medical imidazoles
Clotrimazole (A) and miconazole (B) are medical imidazoles. Each is found as the active
ingredient in around 300 over-the-counter products in Canada to treat athlete’s foot (tinea pedis),
jock itch (tinea cruris), ringworm (tinea corporis), superficial yeast growth on skin (tinea
versicolor), a well as vaginal yeast infections and diaper rash (Wishart et al., 2018). Clotrimazole
can be prescribed or found in over-the-counter medications in forms such as topical creams
(typically 10 mg/g) and 10 mg lozenges. Miconazole is found in slightly higher concentrations for
creams (20 mg/g) and tablets (50 mg) (Wishart et al., 2018). Neither medication is approved for
systemic use.

A

B

C

Figure 2 – Structures of select medical triazoles
Fluconazole (A) is a medical triazole used for the treatment of cryptococcal meningitis, Candida
infections of various types, such as vaginal, systemic, and esophageal, as well as prevention of
fungal lung disease in susceptible populations. It is available by prescription for intravenous use
(2 mg/mL) and by prescription or over-the-counter in the form of 50-200 mg tablets. Voriconazole
(B) is prescribed for intravenous use (10 mg/mL), and in tablet form (50-200 mg); however, it is
not available over the counter (Wishart et al., 2018). It is approved for use for esophageal
candidiasis in addition to invasive aspergillosis, which is intrinsically resistant to fluconazole
(Leonardelli et al., 2016), and Fusarium infections, which are resistant to fluconazole and
itraconazole (Stanzani et al., 2007). Itraconazole (C) is not available over-the-counter or for
intravenous use but can be prescribed for tablet/capsules (65-200 mg) and as an oral solution (10
mg/mL). Itraconazole is approved for a wider variety of fungal infections, including
blastomycosis, histoplasmosis, aspergillosis, and onychomycosis, as well as preventing fungal
infections in cystic fibrosis patients (Wishart et al., 2018).
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According to the Medical Expenditure Panel Survey compiled by the U.S. Department of Health
and Human Services, Agency for Healthcare Research and Quality, fluconazole was the most
widely prescribed antifungal drug with 3.5 million annual prescriptions in the U.S. in 2017,
followed by nystatin and ketoconazole, another medical imidazole, with 2.5 million prescriptions
each (Agency for Healthcare Research and Quality, 2018). Less commonly prescribed antifungal
drugs include clotrimazole, alone or in a mixture with the anti-inflammatory drug metamethasone,
at 1 million and 850,000 annual prescriptions respectively, terbinafine at 1 million prescriptions,
and miconazole with 225,000 prescriptions (Agency for Healthcare Research and Quality, 2018).

1.3 Fate of antifungals in the environment
Due to previous studies implying that soil environments can act as a reservoir of azole-resistant
fungi that can cause mycosis in humans, it is essential to determine what concentration of azole
drugs in the soil can promote antifungal resistance. Pathways leading to azole contamination of
soils include applying agricultural antifungals to product crops against plant-pathogenic fungi,
such as difenoconazole, tebuconazole, and propiconazole (Figure 3), as well as the application of
antifungal-contaminated biosolids to agricultural lands.

A

B

C

Figure 3 – Structures of select agricultural triazoles
Difenoconazole (A), tebuconazole (B), and propiconazole (C) are broad-spectrum fungicides
approved for use in Canada to control fungal growth on turfgrass, wood, and crops such as cereals.
To control plant pathogens, these agricultural triazoles can be applied via foliar application or seed
treatment (Pest Management Regulatory Agency, 2016c, 2016b, 2016a).

During primary treatment of wastewater, solids are allowed to settle, and these solids are then
biologically digested to create biosolids. Biosolids are then applied to agricultural fields as sources

5
of nutrients, such as nitrogen and phosphate, and micronutrients, such as copper, iron,
molybdenum, and zinc. In Ontario, the application of biosolids to agricultural fields is governed
by stringent regulations that consider parameters such as field slope, distance to residential areas,
and amounts of plant-available nitrogen and phosphate (Government of Ontario, 2002).

A 2007 survey of Swedish sewage treatment plants estimated that 41% of purchased miconazole
and all purchased clotrimazole could be accounted for in sewage sludge (Lindberg et al., 2010).
Furthermore, miconazole has previously been detected at concentrations of 477 μg/kg and 341
μg/kg in biosolids originating from Niagara Region sewage treatment facilities (Sabourin et al.,
2012) and the Robert O. Pickard Environmental Centre in Ottawa (Gottschall et al., 2012),
respectively. Clotrimazole was detected at a concentration of 492 μg/kg in biosolids originating
from a Beijing sewage treatment plant (Chen et al., 2013).

Following the application of biosolids, miconazole and clotrimazole persist in soils. A
concentration of 127 μg miconazole/kg soil was detected 400 days following application of the
Ottawa biosolids to a field at a rate of 22 Mg dry weight per ha (Gottschall et al., 2012). Likewise,
plots receiving three annual applications of the Beijing biosolids at a rate of 60 Mg/ha contained
up to 65 and 41 μg miconazole and clotrimazole, respectively, per kg of soil (Chen et al., 2013).
Microcosm studies have shown that the half-life of clotrimazole decreases with temperature, with
a half-life in loam soil of 275 days at 4°C and 68 days at 30°C (Sabourin et al., 2011). In addition,
in sludge-amended sandy-loam soil, the half-life of clotrimazole decreased from 126 to 29 days,
as moisture content increased from 4.5 to 11% (García-Valcárcel & Tadeo, 2012)

1.4 Emergence of resistance to antimicrobial agents
The Centers for Disease Control and Prevention published in its Antibiotic Resistance Threats in
the United States, 2019 report that over 2.8 million cases of antibiotic-resistant infections—mostly
caused by bacteria—in the U.S. were causing over 35,000 deaths per year (CDC, 2019). Multiple
factors lead to the evolution, selection, and spread of antibiotic and antifungal resistance. These
include the ability of the microorganisms to develop resistance due to over-use or inappropriate
use of antibiotic or antifungal drugs, the spread of drug-resistant strains in environments such as
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hospitals, and, in bacteria, the spread of genes conferring drug-resistance to drug-susceptible
bacteria via plasmids, bacteriophages, or uptake of naked DNA (Levy, 2002). More specifically,
fungi can develop resistance to azole drugs via upregulation of drug and toxin-removing efflux
pumps, upregulation of CYP51A1-encoding genes, and modifications of the CYP51A1-azole
binding sites (Fisher et al., 2018).

The development of resistance to fluconazole, the most commonly prescribed azole drug, is
exacerbated by the fact that fluconazole is fungistatic and not fungicidal, thus allowing for
directional selection of the resistant phenotype among exposed isolates, and the fact that
fluconazole resistance can occur by multiple mechanisms (Anderson, 2005). It follows that the
international ARTEMIS Antifungal Surveillance Program detected that fluconazole resistance in
the yeast Candida glabrata increased from 9% to 14% from 1992–2001 to 2001–2007 (Pfaller,
Messer et al., 2009). In addition, from 2005 to 2007, increases in voriconazole resistance in
multiple clinical species of Candida have been found, including in C. famata (from 1% to 6%), C.
norvegensis (0% to 7%), C. lipolytica (0% to 11%), and C. pelliculosa (14% to 17%) (Pfaller et
al., 2010). In addition, Candida auris is a multi-azole resistant pathogen first isolated in 2009;
however, it has been argued that the recent spread of the species may be due to climate change as
opposed to azole overuse (Casadevall, 2019).

1.5 Evidence of cross-resistance between azoles
Several in vitro studies have shown that the evolution of resistance to one azole, whether used for
agricultural or clinical purposes, leads to increased resistance to other azoles. For example,
following gradual adaptation of up to 30 μg/mL tebuconazole over eight weeks, the maize
filamentous fungal pathogen Colletotrichum graminicola showed increased resistance to
clotrimazole and miconazole in a skin infection assay (Serfling et al., 2007). Likewise, isolates of
the plant pathogen Ustilago avenae selected for resistance to the agricultural azole tetraconazole
were also more resistant to clotrimazole, miconazole, and itraconazole than unadapted isolates
(Köller & Wubben, 1989). Another study showed that a Candida parapsilosis strain selected for
lower sensitivity to tetraconazole was also less sensitive to fluconazole, voriconazole, and
itraconazole (Rocha et al., 2016). Simultaneous incubation with promethazine, an efflux pump
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inhibitor, did not lower the minimum inhibitory concentration (MIC) values to fluconazole,
leading to the suggestion that increases in efflux pump activity could not solely be responsible for
the increased resistance to fluconazole after tetraconazole adaptation (Rocha et al., 2016).

A recent study applied spores of triazole-susceptible A. fumigatus containing an antibioticresistance marker and tebuconazole to open fields and greenhouse soil planted with tomatoes (Cao
et al., 2020). After four fungicide applications ov40
r fourteen days, the open fields contained up to 0.72 mg tebuconazole/kg soil, and the greenhouse
soil contained up to 1.24 mg/kg soil. When A. fumigatus strains containing the antibiotic-resistance
marker were isolated and tested for sensitivity against azoles, a higher number of triazole-resistant
isolates were recovered from the greenhouse soils, and this was hypothesized to be due to the
higher tebuconazole concentration. It was concluded that the tebuconazole exposure could induce
resistance to the medical triazoles, itraconazole and voriconazole (Cao et al., 2020).

It follows that isolates that show reduced sensitivities to clotrimazole and miconazole following
long-term exposure will likely show reduced sensitivities to other azole drugs regardless of
whether they are meant for clinical or agricultural use.

1.6 Antifungal resistance between the environment and the
clinic
Recent studies have noted genetic similarities between environmental and clinical fungal isolates
and, thus, have implicated transmission of opportunistic pathogens residing in the environment to
humans. For example, Candida tropicalis with identical identifying genomic sequences have
been isolated from soil, fruits, and the bloodstream of azole-naïve candidiasis patients without
correlation to time and treatment location within the hospital (Chen et al., 2019; Lo et al., 2017).
In addition, because genetically similar isolates of C. krusei have been observed both in clinical
settings and various environmental settings, these isolates were likely transmitted from the
environment to humans (Douglass et al., 2018). These findings have important implications for
clinical azole resistance as the mentioned C. tropicalis strain identified in environmental and
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clinical samples had reduced sensitivity to clinical azoles, and C. krusei is intrinsically resistant
to fluconazole.

Together, these findings beg the question: Is azole-resistance being selected for in the
environment and then causing azole-resistant mycotic infections in humans? Evidence for such a
phenomenon comes from clinical isolates of the filamentous fungi species Aspergillus fumigatus
containing a TR34/L98H or TR46/Y121F/T289A mutation in the Cyp51A-encoding gene. The
TR34/L98H mutation consists of a 34-bp tandem repeat in the promoter region and a leucine to
histidine substitution in codon position 98 in the coding region. Meanwhile the
TR46/Y121F/T289A mutation includes a 46-bp tandem repeat in the promoter region and a
tyrosine to phenylalanine in position 121 and threonine to alanine in position 289 of the coding
region. Computer modelling has suggested that the resistant phenotype of the TR34/L98H
mutant is due to altered binding conformations between azole drugs and the modified Cyp51A
enzymes (Bowyer & Denning, 2014; Snelders et al., 2012). Strains of A. fumigatus with this
mutation can outcross with azole-sensitive strains and, thus, spread geographically (Camps et al.,
2012). In addition, microsatellite genotyping studies have dated the origin of the TR34/L98H
mutation to 1997, shortly after the approval of agricultural azoles such as propiconazole and
tebuconazole in the early to mid 1990’s (Snelders et al., 2012). As well, the tandem repeats of
both the TR34/L98H and TR46/Y121F/T289A mutations are typical of azole-resistance
mutations found in fungal plant pathogens (Chowdhary et al., 2013; Snelders et al., 2009). Given
these points, it is possible that the two mutations originated in the environment before showing
up in clinical settings.

It has also been shown that due to high levels of fungicides, such as tebuconazole,
epoxiconazole, and prothioconazole, waste from flower bulbs, compost waste, and wood
chippings were identified as being particularly conducive to the development of azole-resistant
Aspergillus fumigatus (Schoustra et al., 2019). In addition, a case study of an azole-naïve patient
who developed fatal aspergillosis found genetically identical A. fumigatus strains containing the
TR46/Y121F/T289A mutation throughout the patient’s house months after death (Lavergne et
al., 2017). Altogether, these studies are evidence that A. fumigatus can develop azole resistance
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in the environment and fungi residing in the environment can cause mycotic infections in
humans.

1.7 Fungal ecology
The largest and best-studied subdivisions of the Dikarya kingdom are the Ascomycota and
Basidiomycota. Common fungal pathogens include the candidiasis-causing Ascomycete yeasts
Candida albicans and Candida glabrata, the cryptococcosis-causing Basidiomycete yeasts
Cryptococcus neoformans and Cryptococcus gattii, and the aspergillosis-causing filamentous
fungus Aspergillus fumigatus. Collectively these five species accounted for ~80% of fungal
infections following organ transplants monitored by the American-based Transplant-Associated
Infection Surveillance Network (Pappas et al., 2010).

With the exception of Candida krusei, detection of other common clinically relevant Candida
species in environmental samples has been rare and, in the case of C. albicans, not uncommonly
interpreted as sample contamination (Opulente et al., 2019). Likewise, clinically relevant yeasts
have been described as ‘not common or abundant’ in soils (Yurkov, 2018). However, Opulente et
al. succeeded in obtaining 28 isolates, including major Candida pathogens –C. albicans, C. krusei,
C. parapsilosis, and C. tropicalis—from 931 samples of soil, plant matter, and fruits. Although
the study could not determine if the Candida isolates could actively grow in soil, their isolation
from soils proved that they persist outside of endothermic environmefnts and could possibly be
transferred between endothermic organisms via soil (Opulente et al., 2019). Another study from
2019 questioned the long-held assumption that views C. albicans as an obligate commensal of
endothermic animals (Bensasson et al., 2019). In this work, the authors isolated three strains of C.
albicans from oak trees and suggested that the organisms were long-term inhabitants of the trees
based on their high genetic diversity (Bensasson et al., 2019). On the other hand, the filamentous
fungus A. fumigatus is readily isolated from environmental samples (for example, see Snelders et
al., 2009).

Soil bacterial communities are typically more diverse and contain 2-3× the species richness
compared to soil fungal communities (Peay et al., 2016). In addition, yeasts tend to be less
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abundant than filamentous fungi in soils with counts of yeasts typically being in the range of
hundreds to thousands of cells per gram (Yurkov, 2018). Nonetheless, soil fungi play important
ecological roles, such as organic matter decomposition and nutrient mineralization. Globally,
proximity to the equator and available nitrogen correlates with pathogen richness, moisture-related
parameters correlate with saprotroph richness, and soil alkalinity and the presence of host plants
correlates with ectomycorrhizal richness (Tedersoo et al., 2014). In addition, fungal biomass and
diversity were shown to be associated with increases in nitrogen and nitrate concentration in
grassland and forest soils in Germany (Birkhofer et al., 2012). Below topsoil, species richness
broadly decreases with decreasing carbon availability, leaving mycorrhizal fungi and species able
to break down lignin and tannin predominating lower depths of soils (Peay et al., 2016). Fungal
communities in agricultural soil samples can also be influenced by factors such as tillage practice,
fertilization intensity, and crop growth. For example, Fusarium spp. was found to be positively
associated with conservation tillage while Rhodotorula spp. was positively associated with
conventional tillage (Sommermann et al., 2018).

1.8 Review of Methods
1.8.1

Culture-based surveys of soil fungi

Culture-based surveys of soil fungal communities using a small number of isolation methods tend
to produce collections dominated by a few species. For example, Aljohani et al. isolated 110 yeasts
from 443 Cameroonian agricultural soil samples by inoculating 1 mL of chloramphenicol
containing SD (Sabouraud dextrose) broth with 200 mg soil for 2-7 days at 30°C and then streaking
the liquid enrichments onto yeast extract-peptone-dextrose agar for 48 hours of incubation
(Aljohani et al., 2018). The resulting collection was dominated by Cyberlindnera subsufficiens
(25% of isolates), Cyberlindnera saturnus (14%), Torulaspora globose (19%), and Candida
tropicalis (18%) (Aljohani et al., 2018). Cyberlindnera and Rhodotorula species were also found
to dominate in a study of endophytic yeast of the elm and oak trees, Ulmus parvifolia and Quercus
salicina (Kim & Kim, 2017). Yeasts from the genera Cyberlindnera were also the dominant
endophytic yeast isolated from the roots of the critically endangered fern Mankyua chejuense (Kim
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et al., 2017). Enrichment-free protocols can also produce collections dominated by a few species.
For example, of over 100 yeasts isolated by Slavikova & Vadkertiová from direct plating of a 1%
soil slurry onto two agars at 7°C and 25°C, 80% belonged to four species (Sláviková &
Vadkertiová, 2003).

1.8.2

Ergosterol quantification for estimating biomass

Quantification of ergosterol is a useful biomarker of fungal load in environmental samples,
including soils (reviewed in Djajakirana et al., 1996; Montgomery et al., 2000). As caveats,
however, ergosterol quantification underestimates counts of yeasts relative to filamentous fungi
with a single yeast cell showing ergosterol amounts on the magnitude of 1×10-4 pg and a single
filamentous fungi spore containing 1×10 levels (Pasanen et al., 1999). Also, ergosterol shows
relatively slow degradation over two months in soils unexposed to sunlight (Mille-Lindblom,
Wachenfeldt, & Tranvik, 2004) and soils briefly exposed to fungicides (Zhao, Lin, & Brookes,
2005), complicating the utility of ergosterol for quantifying living biomass.

1.8.3

Antifungal susceptibility testing

The European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and
Laboratory Standards Institute (CLSI, previously NCCLS) developed recommendations for testing
the sensitivity of isolates to clinical antifungal drugs. Both institutions have developed methods
for antifungal susceptibility testing using broth dilutions. In this method, isolates are grown in
broths containing various concentrations of a drug and the lowest drug concentration that leads to
growth inhibition is noted as the minimum inhibitory concentration (MIC). For reference, some
broths are left uninoculated and some isolates are grown in broths containing no drug.

The EUCAST method for testing yeasts isolates was optimized for testing Candida and
Cryptococcus species and tests fluconazole from a range of 0.125 to 64 mg/L and itraconazole and
voriconazole from a range of 0.008 to 4 mg/L. (EUCAST, 2020). In addition, a protocol for
filamentous fungi was optimized for testing Aspergillus spp. and tests itraconazole from 0.0156 to
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8 mg/L and voriconazole from 0.0312 to 16 mg/L (EUCAST, 2015). Both protocols are based on
a 200 μL microbroth dilution assay using RPMI-glucose broth containing 2% glucose. Likewise,
CLSI recommends similar microbroth dilution tests in its M27-A3 (CLSI, 2008a) and M38-A2
(CLSI, 2008b) protocols for testing yeasts and filamentous fungi, respectively.

A second method for testing the susceptibility of isolates to drugs involves streaking an agar plate
with a suspension of an isolate and immediately placing a material containing the drug, such as a
paper disk, onto the agar. The drug then diffuses outward from the material onto the surrounding
agar such that the concentration of the drug steadily decreases in the agar with increasing distance
from the drug-containing material. Following incubation, the distance from the disk at which the
isolate can no longer grow is used as a measure of the isolates' sensitivity. Agar-based
susceptibility tests can be quicker to perform than broth-based tests while still providing reliable
results. Intra- and interlaboratory variation using an E-test strip, which is a plastic strip containing
a gradient of a drug, on RPMI-glucose agar is relatively low making testing relatively reliable.
One review where four laboratories performed 20 replicates of E-tests with C. krusei and C.
parapsilosis isolates tested against ketoconazole and fluconazole showed agreement within a 3
log2dilution range 98-100% of the time (Pfaller et al., 1996).

Based on disk diffusion methods, CLSI produced the M44-A2 protocol (CLSI, 2009) for testing
yeasts, which was optimized for testing Candida species against fluconazole and voriconazole,
and the M51-A method (CLSI, 2010) for testing filamentous fungi. For both protocols, CLSI chose
to use Mueller-Hinton agar—a complex medium—over RPMI (Roswell Park Memorial Institute)
agar—a synthetic medium— due to its greater availability and lower cost at the expense of more
significant batch-to-batch variability (CLSI, 2009). However, the activity of the imidazoles
clotrimazole and miconazole have been shown to be antagonized by complex media such as SD
agar and brain-heart infusion agar, but not present in synthetic media (Ester & Hoeprich, 1976).

To ensure reproducibility, the microbroth-based EUCAST 7.3.1 protocol for testing of yeasts
(EUCAST, 2020) stipulates that the inoculum used for testing must be standardized to 0.5 x 105 to
2.5 x 105 CFU/mL of distilled water while the microbroth-based EUCAST 9.3.1 protocol for
testing filamentous fungi (EUCAST, 2015) stipulates an inoculum size of 2 x 105 to 5 x 105
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conidia/mL. Yeasts are to be grown between 34-37°C on SD or PD agar for 18-48 hours before
adjusted to a set turbidity using a spectrophotometer. Meanwhile, filamentous fungi can be grown
for 2-5 days at 35°C, or longer if sporulation does not occur, on any media that encourages
sporulation. Then, a damp cotton swab is rubbed against filamentous fungi colonies and deposited
into 5 mL distilled water with Tween 20, a surfactant. Next, to standardize the inoculum size, the
suspension is either directly adjusted with distilled water after counting conidia using a
haemocytometer, or the suspension is filtered through an 11 μM filter to filter out hyphae before
using a spectrophotometer to adjust the density of conidia.

1.9 Objectives and hypothesis
Although numerous studies have raised concerns over residual antibiotics in the environment
promoting the development of antibiotic resistance in soil bacteria, less is known about the effects
of residual antifungal drugs on soil fungi. Given that miconazole and clotrimazole persist in the
environment, microplots at Agriculture and Agrifood Canada London Research and Development
Centre (AAFC) have been annually amended with environmentally relevant and excessive
concentrations of miconazole and clotrimazole since 2010. This study aimed to elucidate the
effects that the miconazole and clotrimazole in these plots have had on fungal community
composition and antifungal resistance. My predictions were:
1) Fungal isolates belonging to the same species would show decreased sensitivities to
clotrimazole and miconazole when isolated from the treated versus the control plots
2) The fungal community in the soils containing clotrimazole and miconazole would be
enriched in wildtype strains with intrinsically low sensitivities to the drugs as, over the
years, the drugs inhibited the growth of sensitive strains
3) Long-term exposure to clinical azoles would select for isolates resistant to agricultural
azoles
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2

Methods

2.1 Field experiment
In 2010, a field experiment was initiated at the AAFC-London to evaluate the long-term impact of
biosolid-typical levels of clotrimazole and miconazole exposure on soil fungi. Annually, in June,
solutions of 365 mg/mL miconazole nitrate in dimethyl sulfoxide (DMSO) and 500 mg/mL
clotrimazole in methanol were mixed into four 1 kg portions of soil. These 1-kg portions of soil
were then mixed into 2 m2 microplots to a depth of 15 cm using a rototiller to produce four replicate
microplots containing 1 mg/kg soil and four replicate plots containing 10 mg/kg soil of both
miconazole and clotrimazole. Four replicate plots were left untreated. The plots were randomly
distributed by treatment type across the field and were physically separated by fibreglass frames.
The gray-brown Luvisol soil had previously been classified as having the following properties: a
sand/silt/clay ratio of 18/67/15%, pH of 7.5, cation exchange capacity of 7.5, and organic matter
content of 3.4%. The soil had no known prior treatment with manure or biosolids, and no known
treatment with pesticides or fertilizers since 1986. The microplots were cropped annually with
soybeans (Glycine max var. Harrosoy) and manually weeded. Each spring, eight 20 cm-long soil
cores totalling 1 kg were collected from each plot. These soil samples were sieved and stored at 20°C for long-term storage. On the other hand, soil samples were sampled in August and October
2018, April 2019, and March 2020 and stored at 4°C or 15°C for up to six months prior to being
used for fungal isolation (Figures 4-6).

2.2 Isolation of yeasts and filamentous fungi
To isolate yeasts and filamentous fungi colonies from the soils, first, soil slurries were prepared.
To create soil slurries, five grams of each soil sample were measured out using a metal spatula that
was sterilized with 70% ethanol between samples. The five gram soil aliquots were suspended in
45 mL of 0.002% sodium metaphosphate buffer (Fisher Scientific, Ottawa, ON) in 50 mL conical
tubes (Corning Life Sciences, Corning, NY; or Sarstedt AG, Numbrecht, Germany). Soil slurries
were stored for up to a week at 4°C before being used for fungal isolation. Soil slurries were mixed
using a wrist action shaker (Burrell, Pittsburgh, PA) before being spiked into various broths or
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plated onto multiple types of solid agar (Table 1; Figures 4-6). Soil slurries spiked into broths in
50 mL conical tubes were either rotated on a Roto-Torque (Cole-Palmer, Chicago, IL) or shaken
at ~250 rpm on a shaker (New Brunswick Scientific, Edison, NJ) to encourage yeast-like growth
in the supernatant and filamentous fungi to sink down into the pellet. After a brief incubation, 100
μL of the supernatant was then plated onto solid agar to selectively isolate yeasts. Alternatively,
100 μL of a 1:10 dilution of slurry or 50 or 100 μL of undiluted slurry was directly plated onto
various antibiotic-containing agar plates to give 1, 5, or 10 mg of soil plated per agar plate. To
plate broth supernatants or soil slurries, a metal or glass plate spreader was sterilized in 97%
ethanol and passed over a flame between spreads. For each plating event, soils from all twelve
plots were used, and a negative control of either sodium metaphosphate or MilliQ water was used.
To increase the diversity of isolates and to minimize clonality in the fungal collection, new soil
slurries were routinely prepared between plating events and in general, only one morphologically
identical colony per plate was retained for the collection.

Commercially prepared agars used for isolation of yeasts and filamentous fungi from soils included
dichloran-glycerol 18 agar (DG18) (Fluka, Steinheim, Germany), rose bengal (RB) and yeastmold-11 (YM-11) agar (both from Hardy Diagnostics, Santa Maria, CA), and Sabouraud dextrose
(SD), Mueller-Hinton (MH), malt extract (ME), Czapek-Dox (CZ), and potato-dextrose (PD) agars
(all from Becton, Dickinson and Company, Sparks, MD). Agars made in-house included
Dekkera/Brettanomyces differential medium (DBDM) and glucose-yeast-peptone (GYP) agars.
The PD, MH, and GYP agars were used to support the growth of a wide range of organisms due
to a nutrient-rich composition and a neutral pH. As for selective media, CZ uses nitrate as a sole
nitrogen source, DBDM uses ethanol as sole carbon source, ME and SD both have an acidic pH,
DG selects for osmophilic and xerophilic organisms due to low water activity, and RB agar
contains rose bengal to inhibit the radial growth of certain filamentous fungi.

All agars and broths were amended with antibiotics to inhibit the growth of bacteria and select
agars and broth were amended with selective fungicides to increase the diversity of fungi isolated
overall. Antibiotic stocks of 100 mg/mL chloramphenicol in 97% EtOH, 500 mg/mL streptomycin
in ddH2O, 5 mg/mL chlortetracycline HCl in 0.5 N NaOH and a stock of 100 mg/mL
cycloheximide in ddH2O, were prepared in 15 mL or 50 mL conical tubes, filtered using a 0.22
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μm filter, and stored in conical tubes at 4°C prior to use. All three antibiotics and cycloheximide
were sourced from Sigma-Aldrich (St. Louis, MO). Antibiotics were added to the agar as noted
Following initial isolation, in most cases, yeasts and filamentous fungi were sub-cultured to purity
on the agar used for initial isolation after which axenic yeasts cultures were maintained on
Sabouraud dextrose (SD) agar and axenic fungal cultures were maintained on Mueller-Hinton
(MH) agar at room temperature. Yeasts isolated at 4°C were maintained at 4°C, 15°C or room
temperature, depending on the observed maximum growth temperature. Likewise, filamentous
fungi that were isolated at temperatures over 37°C were either maintained at 37°C or room
temperature, depending on the observed growth rate. Preparation of glycerol stocks for yeasts
varied by the period of isolation (Figures 4-6). On the other hand, filamentous fungal cultures were
swabbed with sterile cotton swabs from growth on MH agar at room temperature and the resulting
fungal fragments were suspended in Milli-Q water. The fungal suspensions were then used to
create 25% v/v glycerol stocks to be frozen at -80°C.
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Table 1 – Composition of Agars and Broths used for Fungal Isolation
With the exception of commercially-prepared RB and YM-11 agars, agars were either prepared in-house or made with the addition of
agar base (Biobasic, Toronto, ON) to commercially-prepared broths. All agars contained 15 g/L of agar with the exception of
commercially-prepared YM-11 agar, which used 13.5 g/L. For enrichment of yeasts, broths identical to YM-11 and RB agar were
prepared in-house with the exception that trypan blue was not added to the YM-11 broth. An additional medium, termed yeast-extract
peptone dextrose (YEPD), was prepared identically to GYP media with double the amounts of peptone and L-glucose. pH values of
media were brought within the ranges shown using 1N NaOH or HCl.

pH at 25°C

CZ
7.3 ±
0.2

DBDM
5.4 ±
0.2

DG18
5.6 ±
0.2

GYP
7.0 ±
0.2

ME
4.7 ±
0.2

MH
7.3 ±
0.1

PD
7.2 ±
0.2

RB
7.2 ±
0.2

SD
5.7 ±
0.2

YM-11
7.5 ±
0.5

10

20
20

Extracts (g/L)
Beef extract
Malt extract
Potato extract
Yeast extract

2
6
4
5

1.2

Nitrogen Source (g/L)
Caesin, acid digested
Peptone, animal sources
Peptone, soy
Sodium nitrate
Yeast nitrogenous base

17.5
5

10
5

3
6.7
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Carbon Source
Ethanol (mL/L)
L-Glucose (g/L)
Maltose (g/L)
Soluble starch (g/L)
Sucrose (g/L)

60
10

20

6
1.8

20

10

20

5

1.5
30
Inorganic Constituents (g/L)

Dipotassium phosphate
Ferrous sulfate
Magnesium sulfate
Monopotassium phosphate
Potassium chloride
Sodium chloride

1
0.01
0.5

5
0.5
1

0.5
1

0.5
5
Additives (mg/L)

Chloramphenicol
Chlortetracycline HCl
Cycloheximide
Dichloran
Rose bengal
Streptomycin
Trypan blue

80

80

100

80

80

80

80

80

80
200

100
2
400

400
30

400

400

400

400

5
400

400
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Figure 4 – Isolation Procedure of Yeasts from August 2018 Soils
Sixteen yeasts were obtained by AAFC technician Andrew Scott (not shown on flowchart) where
all but one isolate was obtained by direct plating of 10 mg of soil onto 0.2-fold strength (0.2×) SD
agar with miconazole and clotrimazole, 0.2× SD agar containing cetrimonium bromide (noted by
the ‘-C’ affix to media names), 0.2× PD, and 0.2× YEPD agars. An additional isolate was obtained
by performing an enrichment for yeasts with 0.2× SD-C broth and streaking the supernatant onto
0.2× SD-C agar using a 10 μL loop. For long-term storage, single colonies were amplified in 5 mL
test tubes at 30℃ with shaking at 250 RPM for 3-7 days using 2 mL of yeast extract-peptonedextrose (YEPD) broth. Glycerol stocks were created using 800 μL of the liquid cultures and 800
μL of 50% glycerol. RT = room temperature.
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Figure 5 – Isolation of Yeasts and Filamentous Fungi from October 2018 Soils
For long-term storage of yeasts, stocks were created by sub-culturing isolates onto solid agar at least twice using single colonies, and
then dispensing colonies from the agar into a 50:50 mix of broth and 50% glycerol using a 10 μL plastic loop.
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Figure 6 – Isolation of Yeasts and Filamentous Fungi from April 2019 Soils
To create long-term stocks, yeasts were sub-cultured on MH agar at the initial isolation
temperature, and colonies were scrapped using a 10 μL loop and deposited in 800 μL of 0.9% NaCl
and 800 μL of 50% glycerol. In addition to the fungi isolated from the above procedures, in
February 2020, soils stored for three months at 15℃ and then 8 additional months at 4℃ were
used to isolate 26 yeasts using a two-day enrichment of 30 mg soil in 0.2× Luria-Bertani broth and
subsequent two-week incubation on 0.2× SD-C agar at room temperature. Seven of these yeasts
were used for antifungal susceptibility testing. However, these yeasts were were not used for
species richness calculations as these yeasts were specifically isolated to increase sample size for
susceptibility testing of yeasts from the treated plots. Six sequenced filamentous fungi were also
isolated by plating 10 mg of soil on 0.2× SD-C agar at 50℃ for one week).
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2.3 DNA extraction from fungal isolates
For isolating genomic DNA from yeasts, a protocol modified from Lõoke et al. (2011) was used.
Briefly, yeast cells were grown for up to one week on SD agar at room temperature or 15℃ and a
sterile 10 μL plastic loop was used to deposit cells into a lysis solution containing 180 μL of 0.22
μm filter-sterilized 200 mM lithium acetate (Sigma, St. Louis, MO) and 20 μL of 10% sodium
dodecyl sulfate in a 1.5 mL microcentrifuge tube. The mixtures were briefly vortexed, incubated
at 70℃ for up to 10 minutes and then centrifuged at 15,000 × g for three minutes. The resulting
supernatant was then used as a starting material for use with the Wizard Genomic DNA
Purification Kit (Promega, Madison, WI). The Isolating Genomic DNA from Yeast protocol
included in the kit was followed starting from the protein purification step except that all
centrifugation steps resulting in nucleic acid pellets were performed at 15,000 × g for 10 minutes.

For isolating DNA from filamentous fungi, bead beating tubes from PowerSoil kits (Qiagen,
Hilden, Germany) were amended with lysis buffer from the kits and half-filled with 50 x 10 mm
blocks of fungal mass growing on MH agar for at least one week. The tube contents were then
processed as per manufacturer’s instructions for soil samples. Alternatively, following
homogenization, bead beating tubes were centrifuged at 15,000 × g for 5 minutes and the
supernatant was used directly as a template for PCR amplification.

2.4 Identification of isolates
Initially, yeasts were grown on SD agar for up to a week and filamentous fungi were grown on
MH agar for up to three weeks, both at room temperature, to group isolates by morphology. To
further group the isolates, DNA was extracted from 88 yeasts representing 15 species and Random
Amplified Polymorphic DNA (RAPD) PCR was performed based on the methods of Aljohani et
al. (2018). In this method, PCR is performed using a single primer that amplifies repetitive
sequences in the genomic DNA and the resulting amplicons are run on an agarose gel to group
closely related strains. Briefly, in 25 μL PCR strip tubes, 10 μL reactions were composed of
0.4×buffer, 0.02 U/mL Taq polymerase, 2.4 mM MgCl2 (all from Promega, Madison, WI), 320
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μM dNTP mix (BBI Biotech, Berlin, Germany), and 1 μM of either the (GACA) 4 (5’GACAGACAGACAGACA-3’) or M13 primer (5’- GTAAAACGACGGCCAG-3’) (Sigma
Aldrich, St. Louis, MO), 2 ng/mL DNA, and autoclaved MilliQ water. The reactions were cycled
using a protocol of denaturation at 98°C for two minutes, amplification for 45 cycles of 93°C for
20 sec, 50°C for 45 sec, and 72°C for 20 sec, followed by a hold at 72°C for six minutes and a cool
down to 4°C. The (GACA)4 and M13 PCR products were combined and run on a 1% agarose gel
at 80V for 1.5-2.5 hours and bands were manually scored. PCR fingerprinting failed for
filamentous fungi, possibly due to the DNA extraction technique.

Representatives of each fingerprint, as well as each morphologically unique isolate, were identified
by

sequencing

~250

bp

of

the

ITS1

region.

The

ITS1-F

forward

(5'-

CTTGGTCATTTAGAGGAAGTAA-3') (Gardes & Bruns, 1993) and ITS2 reverse primer (5'GCTGCGTTCTTCATCGATGC-3') (White et al., 1990) were used. The template used for the
PCR was either yeast colonies grown for less than one-week and suspended in MilliQ water
(ABS600 ~0.2), yeast DNA diluted to 10 ng/mL, or undiluted filamentous fungi DNA. The PCR
mix for one reaction included 1x GoTaq Flexi buffer, 0.006 units/mL Taq polymerase, and 1.5
mM MgCl2 (all from Promega Corporation, Madison, WI), 200 μM dNTP mix (BBI Biotech,
Berlin, Germany) and 0.2 μM of the forward and reverse primers (MilliporeSigma, St. Louis, MO),
10 μL of template, with MilliQ water up to 25 μL. The PCR protocol was denaturation at 95°C for
5 min, amplification for 35 cycles of 94°C for 30 sec, 52°C for 30 sec, and 68°C for 30 sec,
followed by a cooling down to 4°C. Four reactions per sample were performed. After reactions
were pooled, the reactions were checked for purity on a 1% agarose gels for an amplicon size of
250-600 bp and cleaned up using the Wizard SV Gel and PCR clean-up kit (Promega, Madison,
WI). Purified DNA template was adjusted to 3-10 ng/μL using a NanoDrop ND1000 (NanoDrop
Technologies, Wilmington, DE) for quantification and MilliQ water for dilutions. Reactions of 10
μL DNA and 5 μL of 2 μM forward or primer were submitted to Robarts Research Institute
(London, ON) for Sanger sequencing.

Sequences were trimmed on both ends to exclude regions with significant no call bases, queried
against the GenBank non-redundant nucleotide database using the National Center for
Biotechnology Information’s Basic Local Alignment Search Tool (NCBI BLAST) (Altschul, Gish,
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Miller, Myers, & Lipman, 1990), and then species given the highest scoring matches were
recorded. Partial ITS sequences returning the same highest-scoring species match were aligned
using MUSCLE to look for sub-groups within the species. Higher-order taxonomic classification
corresponding to subkingdom, phylum, subphylum, class, order, family were resolved using
RStudio 3.6.2 and the taxize 0.9.92 package (Chamberlain & Szöcs, 2013) using genus names as
queries and the taxonomy database from NCBI as a reference.

2.5 Viable plate counts
To estimate changes in viable soil fungal counts due to clotrimazole and miconazole exposure,
soils were cultured on agar-solidified RB and DG18 media and the resulting number of colonies
were counted (Table 1). The soil used for the plate counts was stored at 4℃ for less than 2.5 weeks
after being sampled in November 2018 (Figure 5). For each plate, 100 μL of a 100 mg/mL soil
slurry, corresponding to 10 mg of soil, was spread using a sterile plate spreader and incubated at
4℃. Colonies were counted 1.5 weeks and 6 weeks post-incubation for the RB and DG18 plates,
respectively. For a second plating set, soil slurries were prepared in duplicate for each plot from
soils stored at 15℃ for three months after being sampled in April 2019 (Figure 6). As before, 10
mg of each soil slurry was plated onto RB agar, but this time, incubated at 15℃ for four days.
Plates that were overgrown or had large filamentous fungal colonies taking over half of a plate,
which totalled two out of 24 plates, were excluded from plate counts. For plates containing large
filamentous fungal colonies on one end of the plate, or for plates containing too many colonies
overall, half-sections of the plates were counted.

2.6 Ergosterol quantification for estimating biomass
The soil samples used for ergosterol quantification were sampled in August 2018 and stored at 4℃
in the dark in tied, clear plastic bags. The samples were briefly removed from storage twice for
fungal cultivation before being used for ergosterol quantification in March 2020.
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Ergosterol quantification was performed by the AAFC technologist Lou Ann Verellen. Briefly, 5
grams of soil, 3.5 grams of Ottawa Sand (Fisher Chemical, Ottawa ON), and 6 mL of methanol
were combined in a 20 mL polyethylene scintillation vial, vortexed for 10 seconds and mixed using
a wrist action shaker at room temperature for an hour. The mixture was then centrifuged for 10
minutes at 3000 rpm in the Labofuge 6000 (Heraeus Christ, Osterode, Germany) and 1 mL of
supernatant was filtered through a 0.2 mm polytetrafluoroethylene syringe filter and stored in a
1.5 mL microcentrifuge tube.
Following filtration, 20 μL of the supernatant was used for injection and ergosterol was measured
using an Agilent 1260 Infinity high performance liquid chromatography system with a C-18
reverse-phase column (Agilent Eclipse XDB-C18, 4.6mm x 100mm, 3.5μ). Parameters for the
chromatography included a mobile phase of Acetonitrile:Methanol (70:30 v/v), a flow rate of 1.2
mL/min, and temperature of 25 °C. Ergosterol was detected using an Agilent Diode Array detector
at a wavelength of 282 nm.

The retention time was 8.6 min as determined with an ergosterol standard (Sigma-Aldrich, St.
Louis, MO). To produce the ergosterol standard curve, the ergosterol standard (10 mg/mL in
chloroform) was measured at concentrations of 0.125, 0.25, 0.50, 0.75, 1.0, and 2.5 μg/mL.

2.7 Assessing species richness within treatment groups
To assess differences in species richness between control, low treatment, and high treatment plots,
fungal isolates were identified and tallied by treatment type. For yeasts, isolates were clustered at
the species level by sequencing while RAPD PCR and morphology were used to identify isolates
without sequencing data. Seventeen out of 173 yeasts in the collection could not be classified at
the time of writing. For filamentous fungi, only ITS sequencing was used to enumerate species as
sequenced isolates with identical morphologies were shown to belong to different species and
RAPD fingerprinting assays failed to produce discernible banding patterns.
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2.8 Antifungal susceptibility testing
Drug stocks were prepared in 15 mL polypropylene conical tubes (Corning Inc., Corning, NY), by
preparing stock solutions of 12.8 mg/mL clotrimazole (Sigma, St. Louis, MO), miconazole nitrate,
fluconazole, itraconazole, difenoconazole, propiconazole and tebuconazole (all from AK
Scientific, Union City, CA), and 6.4 mg/mL voriconazole (AK Scientific, Union City, CA). DMSO
(Sigma, St. Louis, MO) was used a solvent for all drugs except for clotrimazole and tebuconazole,
which were prepared in 95% ethanol (Commercial Alcohols, Toronto, ON). After allowing the
drugs to dissolve in solution for at least two hours, the solutions were aliquoted into autoclaved
1.5 mL Eppendorf tubes and either used immediately or stored at -80°C. Disks of Qualitative Type
2 Whatman filter paper (Whatman, Maidstone, UK) were cut into disks 7 mm in diameter using a
hole puncher and laid out onto sterile glass Pyrex petri dishes using sterile forceps. The Petri plates
were then wrapped in aluminum foil, autoclaved on a dry setting of 121°C, 15 p.s.i. for 15 minutes
and cooled to room temperature in a laminar flow hood before use.
To prepare azole-containing filter paper disks, fluconazole stocks were diluted to 5 μg/μL,
voriconazole stocks were diluted to 0.2 μg/μL, and all other drug stocks were diluted to 2 μg/μL
in their appropriate solvent. Then, 5 μL of each drug were aliquoted onto the paper disks, while on
the glass Pyrex Petri dishes, in a laminar flow hood, to produce 10 μg disks of clotrimazole,
miconazole, itraconazole, tebuconazole, difenoconazole, and propiconazole, 20 μg disks of
fluconazole, and 1 μg disks of voriconazole. The concentration of each medical azole disk was
equal to the concentration of commercially prepared disks from Rosco Diagnostica (Rosco,
Taastrup, Denmark), with the exception that the commercially prepared fluconazole disks are 25
μg/disk. Disks were dried in a laminar flow hood for a minimum of two hours after drug
application to a maximum of overnight prior to use or storage. For storage, the Pyrex petri dishes
containing the disks were placed in a metal canister with a desiccator, both previously dried and
sterilized at 120°C in an oven but brought to room temperature in the flow hood, and then the
canister was stored at -80°C.

RPMI-glucose agar was prepared by combining 10.4 g RPMI powder (formulation 31800-089;
Thermo Fisher Scientific, Waltham, MA), 18 g dextrose (Sigma, St. Louis, MO), and 15 g agarose
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(Biobasic Canada, Toronto, ON) with 800 mL ddH2O, microwaving until constituents were fully
dissolved, and then autoclaving at 121°C, 15 p.s.i. for 15 minutes. Separately, 34.53 g of MOPS
(Sigma, St. Louis, MO) and 0.15 g L-glutamine (Thermo Fisher Scientific, Waltham, MA) were
combined in 200 mL ddH2O, sterilized through a 0.22 μm filter, and then added to the agarose
mixture. After adjusting the pH of the agar to 7.0 using 6N NaOH, the agar was poured into plates
5 mm thick. Mueller-Hinton agar (Becton, Dickinson and Company, Franklin Lakes, NJ),
formulated to contain 20–25 mg/L calcium and 10–12.5 mg/L magnesium, was prepared per
manufacturer’s direction and poured into agar plates with 5 mm of thickness.

For testing yeasts, single colonies growing on SD agar at room temperature were suspended in
Milli-Q water and adjusted to a turbidity of 0.07-0.11 absorbance at 590 nm in UVette®
spectrophotometry tubes (Eppendorf AG, Hamburg, Germany). In most cases, colonies were
grown for 48-60 hours, however, slow-growing colonies of Mrakia spp., Solicoccozyma terrea,
and Filobasidium oeirense were grown on SD agar for up to one week. Susceptibility testing was
performed by streaking the suspensions on RPMI–glucose agar using a sterile cotton swab and
briefly drying the suspensions prior to disk application. For most isolates, clotrimazole,
miconazole, itraconazole, voriconazole, and fluconazole disks were applied to one agar plate and
difenoconazole, propiconazole, and tebuconazole were applied to a second agar plate. Plates were
incubated at 30°C, or at 15°C if the maximum growth temperature was determined to be below
30°C, typically, for 48 hours, and the zones of inhibition were measured from edge to edge using
a ruler. Sensitivity assays of the slow-growing colonies of Solicoccozyma terrea and Filobasidium
oeirense were incubated for 120 hours. Assays using Mrakia spp. were incubated for 96 hours,
and assays including Vishniacozyma victoriae, Solicoccozyma aeria, Hannaella coprosmae and
select isolates of Bullera alba and Sampaiozyma ingeniosa were incubated for 72 hours. Plates
were also imaged on a flat surface using a levelled gel imager camera alongside an adjacent ruler
for documentation purposes.
For filamentous fungi, 10-100 μL of cryopreserved stock were pipetted onto three spots of a 0.2×
PD agar plate and plates were incubated upright at room temperature for one to three weeks. Fungal
biomass was obtained by gently swabbing colonies with a sterile cotton swab and suspending the
biomass into approximately 500 μL of Milli-Q water in a 1.5 mL microcentrifuge tube. While the
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biomass was not filtered to exclude all but conidia, large hyphal fragments were prevented from
being introduced to the suspension by discarding fragments stuck to the end of the pipette tip.
When possible, suspensions were adjusted to a turbidity of ABS590 = 0.07-0.11. Otherwise, initial
fungal suspensions showing a turbidity below ABS590 = 0.07 were used as-is. Suspensions were
spread with sterile cotton swabs onto MH agar, and Rosco Neo-Sensitabs™ (Rosco, Taastrup,
Denmark) containing 10 μg clotrimazole or miconazole were placed onto the agar, and the plates
were incubated at 25°C for 48-60 hours. Again, plates were imaged using the gel imager; however,
unlike with the yeasts, measurements for zones of inhibition were measured from the images using
the ruler as a guide.

2.9 Quality control for antifungal susceptibility testing
Selected yeasts were tested in duplicate to assess the impact of variation between sets of tests
caused by variation in disk and plate properties, such as composition and dryness, inoculum
preparation, such as density and colony freshness, and testing parameters, such as zone of
inhibition measurements and incubation time. The largest variation was noted for an isolate of
Schwanniomyces occidentalis showing a zone of inhibition to clotrimazole of 36 mm in one test
and 44 mm in another test. Reproducibility also suffered in tests where isolates produced small
zones of inhibition with extensive trailing growth towards a disk. For example, Rhodotorula
isolates initially retested due to showing no zone of inhibitions when tested against miconazole
and itraconazole, later showed zones of inhibition around 10 mm (Table 2). When multiple
measurements of isolates were taken, the average zone of inhibition between trials was used in
subsequent calculations. Filamentous fungi were tested using commercially prepared azole disks
and yeasts tested against agricultural azoles were tested using limited batches of media, limiting
batch variation.

To test for reproducibility using different agars and disk preparation methods, two isolates of
Rhodotorula mucilaginosa were tested in duplicate using paper disks on Mueller-Hinton agar and
two isolates each of Cyberlindnera saturnus and R. mucilaginosa were tested on the standard
RPMI-glucose agar with commercially-prepared 10 μg clotrimazole or miconazole Rosco
Neosensitab disks as opposed to in-house filter paper disks. Mueller-Hinton agar provided less
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definition around the miconazole and itraconazole disks than RPMI-glucose agar, possibly due to
the lack of a dye in the former. Still, the zones of inhibition to clotrimazole were within error range
to those on RPMI-glucose agar. In addition, although the Neosensitab disks were significantly
larger at 10 mm in diameter versus 7 mm in diameter for the filter paper disks, the susceptibility
and resistance phenotypes were identical using the different disks for the C. saturnus and R.
mucilaginosa isolates.

To confirm that zones of inhibition were caused by the drug impregnated into the disk and not the
solvent carrier, preliminary experiments were undertaken with disks containing only the ethanol
or DMSO solvents. In no instances did either solvent inhibit the growth of 25 yeasts (18 C.
saturnus, three R. mucilaginosa, two Debaryomyces hansenii, and two Bullera alba) or 25
filamentous fungi of various species tested.
Table 2 – Average ZOI (mm ± Standard Deviation) of Yeasts Tested using Different Batches
of Media
To check for variation in zones of inhibition measurements with sensitivity testing of yeasts, select
yeasts were tested using different batches of media. Isolate A was identified as Schwanniomyces
occidentalis and tested against three batches of media while other isolates were tested against two
different batches and isolates B and C were identified as Rhodotorula mucilaginosa, isolates D
and E were Cyberlindnera saturnus, isolate F was Bullera alba, and isolate G was
Cutaneotrichosporon terricola. R = resistant phenotype, n.d. = not tested in duplicate.
Clotrimazole Miconazole Fluconazole Voriconazole Itraconazole
Isolate A
40.0 ± 3.3
26.7 ± 2.1
29.0 ± 1.0
35.3 ± 3.3
25.3 ± 0.9
Isolate B
27.5 ± 0.5
10.0/R
R/R
R/R
11.0/R
Isolate C
29.0 ± 0
R/R
R/R
R/R
11.1/R
Isolate D
24.0 ± 0
19.5 ± 0.5
R/R
18.5 ± 1.5
14.0 ± 0
Isolate E
22.5 ± 1.5
20.0 ± 0
R/R
19.0 ± 1.0
14.0 ± 0
Isolate F
35.5 ± 0.5
R/R
R/R
R/R
23.0 ± 2
Isolate G
35.0 ± 1.0
32.0 ± 2.0
n.d.
n.d.
n.d.
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2.10 Determining levels of susceptibility or resistance to
drugs
For tested yeasts, the majority of susceptibility tests to the eight azole drugs either produced large,
clearly-defined zones of inhibition, indicating that an isolate was susceptible to the drug, or no
zone of inhibition surrounding the drug disks, indicating resistance. However, several isolates
tested against particular drug disks showed extensive ‘trailing growth’ indicative of a fungistatic
drug effect. These isolates produced microcolonies directly surrounding the drug disk with colony
size increasing in size with increasing distance to the disk. In these cases, zones of inhibition were
measured from edge-to-edge using normal-sized colonies, as determined by colonies growing in
the absence of drug, as endpoints. Examples of tests returning results and their classification can
be found in the Appendix (Supplementary Figure 1).

2.11 Statistical analysis
To determine if resistance to one azole drug was associated with resistance to another azole drug,
pair-wise comparisons were performed. Contingency tables comparing the number of isolates
determined to be resistant or susceptible to each drug were constructed as shown in the Appendix
(Tables 3 and 4). Fisher Exact tests were performed using an on-line calculator (Stangroom, 2020)
with a significance level of 0.05.

In addition, to estimate the relationship between susceptibility to one drug versus another drug,
linear regression analysis across all isolates was performed using the zones of inhibition to the two
drugs to the same isolate as variables.

Any potential treatment effect on the sensitivity of recovered fungi to the azole drugs by soil
treatment origin was determined using a two-tailed T-test for two independent means and
calculated using an online calculator and a significance level of 0.05 (Stangroom, 2020b). Data
was compiled such that tests that produced no zone of inhibition in the disk diffusion assay, which
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indicated that the tested isolate was resistant to the tested drug, were represented in the dataset
with a zone of inhibition value of zero millimeters.
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3

Results

3.1 Impact of azole exposure on culturable fungal propagules
The azole concentrations in the treated soils steadily increased with annual azole application to an
average, with noted standard deviation between the four treatment plots, of 0.22 ± 0.09 mg/kg of
miconazole and 0.13 ± 0.04 mg/kg of clotrimazole in the low treatment soils and 19.58 ± 3.77
mg/kg of miconazole and 24.95 ± 6.52 mg/kg of clotrimazole in the high treatment soils (Figure

Concentration of Drig in
Low Treatment Plots
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Figure 7 – Concentration of Azoles in the Low and High Treatment Plots Over Time
Average concentration of the drugs in the four low and four high treatment plots collected prior
to annual drug application is shown with the error bars showing standard deviation in azole
concentrations between the plots.
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The impact of long term fungicide exposure on viable populations of filamentous fungi and yeasts
was evaluated by viable plate counts on RB and DG agar using soils sampled in 2018 following
nine annual drug applications. Statistical tests performed using a two-tailed T-test for two
independent means (Stangroom, 2020b) using the plate count data found higher colony numbers
on plates plotted with control soil than plates plotted with high treatment soil on RB agar (p≤0.01
for incubations at both 4℃ and 15℃) but this difference was not seen on the DG agar incubated
at 4℃ (p=0.32) (Figure 8).
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Plating conditions
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Figure 8 – Plate Counts from Soils Receiving No, Low, or High Azole Treatments
Plate counts show reduced fungal load in high treatment plots compared to control plots on RB
agar bur not DG agar. An outlier plate from the control plot #26 soil with 260 CFU/g soil and an
outlier plate from the high treatment soil with 1,800 CFU/g soil were excluded from the RB agar
incubated at 15℃ bar chart; however, even with these outliers p=0.01 between the control and
high treatment plots. Significant differences between treated plots versus controls are marked with
an asterisk.
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In addition, to estimate fungal biomass, ergosterol in extracts of soil in August of 2018 was
quantified by high performance liquid chromatography (Figure 9). The ergosterol concentration in
the high treatment versus control soils was significantly lower in the soils.
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Figure 9 – Ergosterol Content in Control versus Azole-treated Soils
Ergosterol decreased in the high treatment plots receiving annual applications of azoles versus
untreated control plots after eight years of annual azole application.

3.2 Fungal cultivation and isolation
Soil from each of the 12 plots were plated onto 0.2× strength SD and 0.2× PD agar amended with
1 mg/L miconazole and 1 mg/L clotrimazole in DMSO (Figure 4). For the 0.2× SD agar plates,
one of four plates inoculated with control soil yielded bacterial growth, and of the four plates
inoculated with high treatment soil, one showed bacterial growth, and another showed filamentous
fungi growth. No growth was observed on any other plate after eight days. On 0.2× PD agar,
microbial growth was noted on all four plates containing high treatment soil, two of four plates
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containing low treatment soils, and none of the four plates containing control soils (Figure 10).
Organisms from these plates were not retained in the collection.

A

B

Figure 10 – Observations from Azole-treated Soils Plated on Antifungal-containing Media
Growth was observed on 0.2-strength potato dextrose plates containing clotrimazole and
miconazole when plated with the high treatment soils but not the control soils. None of the plates
plated with the four control soils produced growth (A), but all of the plates plotted with high
treatment soil produced growth (B).

Overall, 42 yeasts were obtained from soils sampled in August 2018. All obtained isolates from
the plating on DBDM agar matched to Cyberlindnera saturnus and all but two of thirty isolates
obtained on the 0.2× strength media containing C-TAB corresponded to C. saturnus, Rhodotorula
mucilaginosa, or Bullera alba.

Seventy-three yeasts were isolated from the October 2018 soils. C. saturnus was the only species
isolated on the CZ agar, and was the predominant species isolated from the YM-11 agar, along
with R. mucilaginosa, and the ME agar, along with R. mucilaginosa and Debaryomyces spp. The
yeasts from the 4℃ incubations were more diverse with, among 15 isolates from each set, 11
species from the RB agar and more than eight species from the DG agar. Anaerobic incubation
yielded few yeasts, five among two sets of SD and RB agar plates, with isolates belonging to
Sampaiozyma ingeniosa (n=2), Hannaella coprosmae, D. hansenii, and R. mucilaginosa. In
addition, fifty-five filamentous fungi that were used for sensitivity testing were isolated from the
October 2018 soils. Mucor and Clonostachys species were the predominant isolates from the RB
agar and Cladosporium and Mortierella species were the predominant isolates from the 0.2× PDC agar.
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From the soils sampled in April 2019, forty-two yeasts from more than nine species were obtained
from the enrichment in MH broth and incubation on MH agar. The high efficiency of this isolation
may be attributed to the fact that the soils were put into enrichment within days of being sampled
from the field with a 15℃ storage in the interim. In addition, forty-five filamentous fungi used for
sensitivity testing were obtained from the soils. Of note, the isolates from the incubation on GYP
at 15℃ were dominated by Mucor and Mortierella species while the MH incubation at 50℃
showed growth of the pathogen Aspergillus fumigatus.

3.3 Identification of fungal isolates
Of the 173 yeasts isolated prior to February 2020, 81 were identified by ITS sequencing, 43 were
identified by a combination of RAPD PCR and morphology and 46 were preliminarily identified
by morphology only. Paired-end sequencing of 26 amplicons produced an identical overlapping
sequence that could be used for identification so single-end sequencing was used
thereafter. Sequenced isolates from the yeast collection yielded 31 unique ITS sequences
representing 28 species (Table 3). Four isolates gave less than 99% ID to any isolate given by
NCBI BLAST and one isolate did not have any close matches to any other classified organism in
the database.

For initial identification, all yeasts were streaked onto 1× SDA and checked after at least one week
of growth at room temperature. C. saturnus was distinguished by white colonies showing a raised
centre surrounded by web-like growth while D. hansenii was distinguished by flat, white colonies
and B. alba showed small, beige colonies. Meanwhile, Rhodotorula showed pink-red, smooth,
sometimes mucoid, colonies and Wang et al. (2015) was used as a guide to distinguish
Rhodotorula from similarly pigmented yeasts.

Following grouping by morphology, RAPD PCR using genomic DNA from 88 yeasts was used to
further group together isolates with identical morphologies (Figure 11).
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Figure 11 – Representative RAPD PCR Gel for Identification of Cyberlindnera saturnus
PCR fingerprints highlighted in green were identified by ITS sequencing as Cyberlindnera
saturnus and all other isolates were assumed to be Cyberlindnera saturnus due to similar
fingerprints and morphology.

Yeasts showing unique morphologies or RAPD PCR fingerprints in addition to representative
isolates from yeasts with identical morphologies and RAPD PCR fingerprints were sequenced.
Overall, by morphology only, 11 isolates were assigned to Cyberlindnera saturnus, 12 isolates to
Rhodotorula, three isolates to Debaryomyces, and one isolate to Bullera alba. An additional 30
isolates were identified as C. saturnus, 10 isolates were identified as R. mucilaginosa, and three
isolates were identified as D. hansenii using a combination of morphology and by sequencing a
representative of a PCR fingerprint.
For filamentous fungi, suspensions of filamentous fungal colonies were aliquoted onto 0.2× PDA
and 1× MH agar in triplicate. Colonies were imaged following adequate growth. By morphology,
four isolates were identified as Mucor spp., three isolates each as Cladosporium spp., Clonostachys
spp., and Mortierella spp., and two isolates as Aspergillus species.
In addition, partial ITS sequencing was performed on 73 filamentous fungal isolates from the
collection, yielding 27 unique ITS sequences representing 22 species (Table 4).

While species-level resolution was obtained for most isolates, the sequencing could not distinguish
between the members of certain species-complexes, such as the Fusarium incarnatum-equiseti and
Cladosporium cladosporioides species complexes, as well as Aspergillus wentii and closely related
species and D. hansenii and closely related species (Supplementary Tables 1 and 2).
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Table 3 – Community Composition of Yeasts Isolated from the Soils.
Isolate counts were primarily identified by ITS sequencing, with sequences provided in Supplementary Table 1.0., with counts of isolates
preliminarily identified by morphology or RAPD PCR noted by parentheses. A single yeast isolate from the high treatment plot, noted
as ‘Isolate FK01_169’, showed no significant match in the NCBI database even when using pair-ended sequencing.

Phylogenetic Data of Isolate

Count by Plot Origin

Phylum

Class

Order

Family

Genus

Species

Control

Low

High

Basidiomycota

Tremellomycetes

Tremellales

Bulleraceae

Bullera

alba

2 (1)

3

3

Basidiomycota

Tremellomycetes

Trichosporonales

Trichosporonaceae

Cutaneotrichosporon

terricola

1

Ascomycota

Saccharomycetes

Saccharomycetales

Phaffomycetaceae

Cyberlindnera

saturnus

2 (12)

4 (22)

5 (7)

Basidiomycota

Tremellomycetes

Cystofilobasidiales

Cystofilobasidiaceae

Cystofilobasidium

infirmominiatum

2

2

Basidiomycota

Tremellomycetes

Cystofilobasidiales

Cystofilobasidiaceae

Cystofilobasidium

capitatum

Ascomycota

Saccharomycetes

Saccharomycetales

Debaryomycetaceae

Debaryomyces

nepalensis,
hansenii,
vietnamensis (A)

1 (2)

Ascomycota

Saccharomycetes

Saccharomycetales

Debaryomycetaceae

Debaryomyces

nepalensis,
hansenii,
vietnamensis (B)

1

Ascomycota

Saccharomycetes

Saccharomycetales

Saccharomycetales

Diutina

catenulata

1

Basidiomycota

Tremellomycetes

Filobasidiales

Filobasidiaceae

Filobasidium

oeirense

Basidiomycota

Tremellomycetes

Filobasidiales

Filobasidiaceae

Goffeauzyma

gastrica

1

Basidiomycota

Tremellomycetes

Tremellales

Bulleribasidiaceae

Hannaella

coprosmae

1

Basidiomycota

Tremellomycetes

Tremellales

Bulleribasidiaceae

Hannaella

oryzae (A)

1

Basidiomycota

Tremellomycetes

Tremellales

Bulleribasidiaceae

Hannaella

oryzae (B)

1

Basidiomycota

Microbotryomycetes

Leucosporidiales

Leucosporidiaceae

Leucosporidium

creatinivorum,
yakuticum, scottii

1

Basidiomycota

Tremellomycetes

Cystofilobasidiales

Mrakiaceae

Mrakia

arctica, gelida

Basidiomycota

Tremellomycetes

Cystofilobasidiales

Mrakiaceae

Mrakia

blollopis

2

Basidiomycota

Tremellomycetes

Cystofilobasidiales

Mrakiaceae

Mrakia

arctica

1

1
1 (1)

1

1
3

2 (3)
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NA

NA

NA

NA

NA

FK01_169

1

Basidiomycota

Tremellomycetes

Tremellales

Rhynchogastremataceae

Papiliotrema

flavescens

Basidiomycota

Microbotryomycetes

Sporidiobolales

Sporidiobolaceae

Rhodotorula

mucilaginosa

8 (5)

4 (7)

Basidiomycota

Microbotryomycetes

Sporidiobolales

Sporidiobolaceae

Rhodotorula

graminis

3

1

Basidiomycota

Microbotryomycetes

Sporidiobolales

Sporidiobolaceae

Rhodotorula

babjevae

1

Basidiomycota

Microbotryomycetes

Microbotryomycetes

Chrysozymaceae

Sampaiozyma

ingeniosa

2

Ascomycota

Saccharomycetes

Saccharomycetales

Debaryomycetaceae

Schwanniomyces

occidentalis

Basidiomycota

Tremellomycetes

Filobasidiales

Piskurozymaceae

Solicoccozyma

terrea

Basidiomycota

Tremellomycetes

Filobasidiales

Piskurozymaceae

Solicoccozyma

aeria

Basidiomycota

Tremellomycetes

Cystofilobasidiales

Mrakiaceae

Tausonia

pullulans (A)

Basidiomycota

Tremellomycetes

Cystofilobasidiales

Mrakiaceae

Tausonia

pullulans (B)

1

Basidiomycota

Tremellomycetes

Tremellales

Bulleribasidiaceae

Vishniacozyma

sp. isolate C220

1

Basidiomycota

Tremellomycetes

Tremellales

Bulleribasidiaceae

Vishniacozyma

heimaeyensis,
foliicola

1

Basidiomycota

Tremellomycetes

Tremellales

Bulleribasidiaceae

Vishniacozyma

victoriae

1

2

8 (11)

3

1
1
1
1

1

1

1

40
Table 4 – Community Composition of Filamentous Fungi Isolated from Soils. Sequences are provided in Supplementary Table 2.
Phylogenetic Data of Isolate

Count by Plot Origin

Phylum

Class

Order

Family

Genus

Species

Control

Low

Ascomycota

Leotiomycetes

Leotiomycetes

Leotiomycetes

Acremonium

sp. MJ35

Ascomycota

Sordariomycetes

Sordariales

Chaetomiaceae

Acrophialophora

levis

1

2

Mucoromycetes

Mucorales

Mucoraceae

Actinomucor

elegans (A)

3

1

Mucoromycetes

Mucorales

Mucoraceae

Actinomucor

elegans (B)

1

Ascomycota

Sordariomycetes

Hypocreales

Stachybotryaceae

Albifimbria

verrucaria,
viridis

1

Ascomycota

Eurotiomycetes

Eurotiales

Aspergillaceae

Aspergillus

fumigatus,
fumigatiaffinis

1

Ascomycota

Eurotiomycetes

Eurotiales

Aspergillaceae

Aspergillus

[multiple]

1

Ascomycota

Dothideomycetes

Capnodiales

Cladosporiaceae

Cladosporium

[multiple]

Ascomycota

Sordariomycetes

Hypocreales

Bionectriaceae

Clonostachys

rosea (A)

Ascomycota

Sordariomycetes

Hypocreales

Bionectriaceae

Clonostachys

rosea (B)

Ascomycota

Sordariomycetes

Hypocreales

Nectriaceae

Fusarium

oxysporium

Ascomycota

Sordariomycetes

Hypocreales

Nectriaceae

Fusarium

Ascomycota

Sordariomycetes

Hypocreales

Clavicipitaceae

Ascomycota

Sordariomycetes

Hypocreales

Mucoromycetes

High
1

1

1

2
4

8

5

1

1

3

1

1

incarnatumequiseti

1

1

Metarhizium

robertsii

1

1

Clavicipitaceae

Metarhizium

marquandii

1

1

Mucorales

Mucoraceae

Mortierella

alpina (A)

Mucoromycetes

Mucorales

Mucoraceae

Mortierella

alpina (B)

Mucoromycetes

Mucorales

Mucoraceae

Mortierella

alpina (C)

1

Mucoromycetes

Mucorales

Mucoraceae

Mortierella

gamsii

1

Mucoromycetes

Mucorales

Mucoraceae

Mortierella

hyalina

1

2

1
1
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Mucoromycetes

Mucorales

Mucoraceae

Mucor

circinelloides

1

Ascomycota

Eurotiomycetes

Eurotiales

Aspergillaceae

Neosartorya

udagawae

1

Ascomycota

Eurotiomycetes

Eurotiales

Aspergillaceae

Penicillium

oxalicum (A)

1

Ascomycota

Eurotiomycetes

Eurotiales

Aspergillaceae

Penicillium

oxalicum (B)

1

Ascomycota

Eurotiomycetes

Eurotiales

Aspergillaceae

Penicillium

novaezeelandiae

1

Ascomycota

Sordariomycetes

Glomerellales

Plectosphaerellaceae

Plectosphaerella

cucumerina

1

Ascomycota

Sordariomycetes

Hypocreales

Ophiocordycipitaceae

Purpureocillium

lilacinum

2

Mucoromycetes

Mucorales

Lichtheimiaceae

Rhizomucor

variabilis

3

1
2

4

3
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3.4 Fungal population structure analysis
When looking at yeasts, the collection from the control plots have notably more species than those
from the high treatment plots. Of 34 sequenced yeasts isolates from the control plots and 27 isolates
each from the low treatment and high treatment plots, 18 (52% of identified isolates), 15 (55%),
and 10 unique species (37%) were observed (Table 3), respectively. On the other hand, for
filamentous fungi, 17 species of 26 identified isolates (65%), 17 species of 31 isolates (55%), and
10 species of 17 (59%) isolates were observed from the control, low, and high treatment plots,
respectively (Table 4). Although the yeast collection from the high treatment plots has a notably
lower species richness than the yeast collection from the control plots, a similar effect was not seen
with filamentous fungi, possibly due to under-sampling of the filamentous fungi community.

3.5 Sensitivity of isolates to drugs
With respect to the medical imidazoles, clotrimazole and miconazole, of 138 tested yeasts to each
drug, 93.5% and 86.2% of isolates were determined to be sensitive to clotrimazole and miconazole,
respectively. Of the sensitive isolates, 3.9%, were determined to be only weakly susceptible to
clotrimazole but notably more, 16.8%, were weakly susceptible to miconazole (Figure 12).

In contrast to the medical imidazoles and agricultural triazoles, the percentage of sensitive isolates
to the medical triazoles fluconazole and voriconazole was significantly lower. Of 119 tested
isolates, only 14.3% and 58.9% of isolates showed sensitivity to fluconazole and voriconazole,
respectively. On the other hand, most isolates, 94.1% of 119 isolates, were sensitive to
itraconazole. The percent of weakly susceptible isolates was relatively high with 17.6%, 11.4%,
and 12.5% of susceptible isolates to fluconazole, voriconazole, and itraconazole, respectively,
being defined as weakly susceptible (Figure 12).

With respect to the agricultural triazoles, 100% of 104 and 98 isolates tested against
difenoconazole and tebuconazole, respectively, showed a sensitive phenotype by the end of the
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standard assay. Meanwhile, 93.3% of 104 isolates tested against propiconazole showed a sensitive
phenotype (Figure 12).
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Figure 12 – Distribution of Susceptibilities of Yeasts Tested against Various Azoles
Sensitivity of yeasts isolated from all soils tested against eight azole drugs show that the tested yeasts were most susceptible to the tested
agricultural triazoles difenoconazole, propiconazole, and tebuconazole, followed by the medical imidazoles clotrimazole, miconazole,
and then the medical triazoles voriconazole, itraconazole, and fluconazole. Susceptibility of isolates to the drugs were ranked by diameter
of the zones of inhibition that the drug disks produced by a disk diffusion assay.
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3.6 Cross-resistance between drugs against yeasts
Overall, resistance to voriconazole was associated with resistance to all other medical drugs and
propiconazole (p<0.001 for each pair-wise comparison) (Supplementary Table 3.1-3.5). Also,
resistance to itraconazole was correlated with resistance to fluconazole (p=0.002; Supplementary
Table 3.6) and resistance to either was significantly correlated with resistance to miconazole
(Supplementary Table 3.7- 3.8). However, resistance to clotrimazole was not associated with
resistance to miconazole (p=0.107; Supplementary Table 3.9), fluconazole (p=0.050;
Supplementary Table 3.10), or itraconazole (p=0.123; Supplementary Table 3.11). As for the
agricultural triazoles, resistance to propiconazole was associated with resistance to the medical
imidazoles, clotrimazole (p<0.001; Supplementary Table 3.12) and miconazole (p<0.001;
Supplementary Table 3.13), in addition to voriconazole, but not to itraconazole (p=0.479;
Supplementary Table 3.14) or fluconazole (p=1; Supplementary Table 3.15). Analyses of crossresistance could not be made for difenoconazole and tebuconazole toward the other drugs as all
isolates tested against these two drugs were susceptible.

Cross-resistance to multiple drugs was often associated with particular species. Strains of Bullera
alba were frequently multi-drug resistant with two out of nine tested strains being resistant to
clotrimazole, miconazole, voriconazole, fluconazole, and propiconazole and an additional strain
being sensitive to all of the above drugs except clotrimazole. In addition, all tested Rhodotorula
mucilaginosa isolates were resistant to fluconazole, with the majority of isolates also being
resistant to voriconazole, and four out of 41 strains showing complete resistance to miconazole
and itraconazole as well. In addition, five out of six Sampaiozyma ingeniosa strains were resistant
to miconazole, voriconazole and fluconazole.

Regression analysis did not indicate that the extent of sensitivity, as measured by the size of the
zone of inhibition, for a given isolate to any azole was directly correlated with the sensitivity to
any other azole (Table 5).
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Table 5 – Regression Analysis using ZOI (mm) of the Same Isolate Tested Against Two Drugs as Variables. R2 values shown.
Clotrimazole
0.00
0.01
0.01
0.01
0.41
0.05
0.22

Miconazole
Voriconazole
Itraconazole
Fluconazole
Difenoconazole
Propiconazole
Tebuconazole

Miconazole

Voriconazole

Itraconazole

Fluconazole

Difenoconazole

Propiconazole

0.46
0.37
0.19
0.06
0.45
0.10

0.35
0.51
0.22
0.35
0.15

0.16
0.03
0.12
0.02

0.38
0.21
0.20

0.01
0.50

0.09

Table 6 – Mean ZOI (mm ± standard deviation) of Isolates Tested Against Azoles by Plot Type Origin.
Clotrimazole Miconazole Voriconazole Itraconazole Fluconazole Difenoconazole Propiconazole
Yeasts
Control
Low treatment
High treatment

23.5 ± 10.7
22.8 ± 7.8
21.9 ± 11.8

14.3 ± 7.3
14.4 ± 6.3
11.7 ± 8.0

Filamentous fungi
Control
Low treatment
High treatment

22.2 ± 8.8
25.2 ± 11.6
21.9 ± 2.2

17.5 ± 11.6
17.2 ± 11.9
13.1 ± 11.8

8.5 ± 12.4
12.7 ± 10.2
90.0 ± 11.3

14.8 ± 7.1
14.4 ± 5.5
12.0 ± 6.3

66.0 ± 10.8
81.0 ± 8.3
44.0 ± 7.1

42.4 ± 9.9
34.3 ± 9.5
38.7 ± 9.1

27.3 ± 10.9
28.5 ± 9.1
25.9 ± 11.5

Tebuconazole
31.6 ± 6.3
30.2 ± 7.4
32.6 ± 2.6
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3.7 Susceptibility patterns of isolates to medical imidazoles
The susceptibility of isolates obtained from control and treated soils toward clotrimazole and
miconazole were not found to be different. The average zone of inhibition (ZOI), with samplebased standard deviation to clotrimazole was 23.5 ± 10.7 mm, 22.8 ± 7.8 mm, and 21.9 ± 11.8 mm
when testing yeasts from the control (n=50), low (n=53), and high treatment (n=43) plots,
respectively (Table 6). The average ZOI when testing 33 filamentous fungi from the control plots,
31 isolates from the low treatment plots, and 24 isolates from the high treatment plots was 22.2 ±
8.8 mm, 25.2 ± 11.6 mm, and 21.9 ± 2.9 mm, respectively (Table 6). In both cases, As shown by
a two-tailed T-test for two independent means, there was no significant difference in average zone
of inhibition between tests using isolates from the control versus low treatment plots (p=0.68 for
yeasts, p=0.23 for filamentous fungi) or between the control versus high treatment plots (p=0.43
for yeasts, p=0.88 for filamentous fungi). Likewise, the average ZOI using miconazole disks and
yeasts from the control, low, and high treatment plots showed no difference in susceptibilities
between yeasts from the control plot versus the low treatment plots (p=0.92), or versus the high
treatment plots (p=0.12) (Table 6). Similarly, with respect to all tested filamentous fungi, the
average ZOI using control versus low treatment-origin isolates was not statistically significant
(p=0.19), nor was the difference when testing control versus high treatment-origin yeasts (p=0.17)
(Table 6).

The sensitivities of isolates from within a given species were tested to clotrimazole and miconazole
to compare the degree of variation from isolates originating from the control plots with isolates
originating from the treated plots. On a species-level, zones of inhibition were very similar when
testing 53 Cyberlindnera saturnus isolates against clotrimazole and miconazole, with average ZOI
not being statistically significantly different when testing isolates from the control versus low
treatments (p=0.90) and control and high treatments (p=0.63) (Figure 13). A similar lack of
treatment effect was seen with 17 Clonostachys rosea isolates and 10 Rhizomucor variabilis
isolates tested against the medical imidazoles (Figure 13).

Although Rhodotorula isolates from the control treatment appeared to be more resistant to
clotrimazole than the isolates from the high treatment, with an average zone of inhibition of 34.2
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± 2.7 mm when testing the control-origin isolates versus 37.2 ± 2.6 mm when testing the high
treatment-origin isolates (p=0.006), there was no statistically significant difference in average ZOI
when testing control versus low-treatment origin isolates (p=0.11) at 34.2 ± 2.7 mm versus 36.1 ±
3.1 mm (Figure 13).

To further test Rhodotorula isolates against clotrimazole, two additional tests were performed.
Isolates were grown on SD agar plates at room temperature and then sub-cultured on MH agar and
incubated for approximately 12 hours at 30℃. Following growth, a 10 μL loop of cells was used
for susceptibility testing using RPMI-glucose agar and Neosensitab disks. Susceptibility tests were
then performed except seven isolates each from the control and high treatment plots were incubated
with reduced oxygen by incubation in a large BD GasPak EZ container (Becton, Dickinson and
Company, Franklin Lakes, NJ) containing one Mitsubishi AnaeroPouch-MicroAero pouch
(Mitsubishi Chemical Holdings, Tokyo, Japan), and 17 isolates from the control plots and 11
isolate from the high treatment plots were incubated under standard conditions for seven days.
Although two MicroAero pouches are needed to create the standard microaerophilic environment
in a large GasPak EZ container, a Mitsubishi Anaero-Indicator indicated reduced oxygen
concentration within the container throughout the incubation period of 48 hours. In both cases,
Rhodotorula isolates from the high treatment plots were not any more or less susceptible to
clotrimazole then those from the control plots (p=0.18 for the reduced oxygen incubation, and
p=0.37 for the seven-day incubation). Interestingly, in both cases this time, isolates from the
control plots appeared to be more susceptible to the clotrimazole than those from the high treatment
plots with average zones of inhibition of 37.0 ± 2.1 mm versus 34.7 ± 3.6 for the reduced oxygen
trial and 34.2 ± 2.4 versus 33.1 ± 4.6 mm for the seven-day incubation. Overall, given the increased
testing, it appears that the initial results of Rhodotorula isolates from the high treatment being
more susceptible to clotrimazole than isolates from the control was due to a sampling error.

3.8 Isolates highly susceptible to medical imidazoles
Eleven yeasts, representing 7.6% of the collection, were considered to be highly susceptible to
miconazole due to ZOI measurements being greater than or equal to 25.0 mm (Figure 12). These
isolates were also susceptible to clotrimazole and were largely isolated from the plots receiving no
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azole fungicides. The isolates represented 17% of tested isolates from the control plots (n=8 of 47)
and were identified as Bullera alba, Cutaneotrichosporon terricola, Diutina catenulata,
Hannaella oryzae (n=2), Mrakia arctica, Sampaiozyma ingeniosa, and Vishniacozyma victoriae,
3.8% of isolates from the low treatment plots (n=2 of 53) and included Schwanniomyces
occidentalis and Solicoccozyma aeria, and 4.5% of tested isolates from the high treatment plots
(n=2 of 44) which included a Bullera alba isolate and an unidentified psychrophilic isolate. As
calculated by a Fisher exact T-test, the proportion of isolates highly susceptible to miconazole was
statistically significant between the control and low treatment plots (p=0.04; Supplementary Table
4.1) but not between the control and high treatment plots (p=0.09; Supplementary Table 4.2).
On the other hand, when defining yeasts highly sensitive to clotrimazole as having a ZOI ≥ 300
mm in diameter (n=51) in the disk diffusion assays, 46%, 26%, and 32% of control, low treatment,
and high treatment-origin isolates were defined as highly susceptible. Increasing the threshold for
high susceptibility to a ZOI ≥ 350 mm included 30 isolates from all plots and led to 24%, 17%,
and 20% of the control, low treatment, and high treatment collections falling under the definition.
Given the lack of a treatment effect, isolates highly sensitive to clotrimazole were not analyzed
further.
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Figure 13 – Sensitivities of Selected Species to Clotrimazole and Miconazole
Sensitivity assays with select yeasts and filamentous fungi species against 10 μg clotrimazole disks
shows a significant difference in zones of inhibition when testing R. mucilaginosa isolates from
the control versus high treatment plots. No other statistically significant pair-wise difference was
detected. Likewise, sensitivity assays with selected yeasts and filamentous fungi species against
10 μg miconazole disks showed no differences in average zones of inhibition based on soil type
origin of the isolates. Isolates of Rhizo. variabilis were resistant to miconazole.
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3.9 Susceptibility patterns of isolates to medical triazoles
Of 146 yeasts tested against itraconazole, the average ZOI using isolates from the control plots
versus the high treatment plots was slightly higher at 14.8 ± 7.1 versus 12.0 ± 6.3 mm (p=0.06).
Nonetheless, C. saturnus, R. mucilaginosa, and D. hansenii isolates from the control versus high
treatment plots were not significantly more or less sensitive to itraconazole (p=0.35, p=0.46, and
p=0.44, respectively) (Figure 14). Similarly, among 96 tested yeasts against voriconazole, there
was no significant difference in average ZOI when testing isolates from the control versus low
treatment plots (p=0.37) or high treatment plots (p=0.13) to the disks. Likewise, no difference in
average ZOI to voriconazole was found when testing C. saturnus isolates from the control versus
the low treatment plots (p=0.88) or versus the high treatment plot (p=0.17) (Figure 14). Only 25
of 158 tested yeasts were susceptible to fluconazole but, overall, no significant difference was
found in average ZOI when testing isolates from the control versus treated plots.

3.10 Susceptibility patterns of isolates to agricultural triazoles
Similar to the medical imidazoles and medical triazoles, for the agricultural triazoles, in general,
no statistically significant differences were found between the average zones of inhibition for
isolates from the control plots (n=38 to 39 for each drug) versus the low treatment plots (n=38 for
difenoconazole and propiconazole, n=30 for tebuconazole), or for the control versus the high
treatment plots (n=34 for difenoconazole and propiconazole, n=30 for tebuconazole). For isolates
tested against the propiconazole disks, the average zones of inhibition was 27.3 ± 109 mm, 28.5 ±
91 mm, 25.9 ± 11.5 mm for control, low treatment, and high treatment-origin isolates, respectively
and for isolates tested against tebuconazole, the averages were 31.6 ± 6.3 mm, 30.2 ± 7.4 mm, and
32.6 ± 6.2 mm, respectively (Table 6). However, isolates from the low treatment plot appeared to
be significantly more resistant to difenoconazole than those from the control treatment plots
(p=0.0004) with an average zone of inhibition of 34.3 ± 9.5 mm for isolates from the low treatment
plot versus 42.4 ± 9.9 mm for the isolates from the control plots (Table 6). When the average zone
of inhibition from the control plot isolates was compared to that of the high treatment isolates, 38.7
± 9.1 mm, the difference was not significant (p=0.11) (Table 6). While the average zones of
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inhibition toward the three agricultural azoles for the yeast Cyberlindnera saturnus, Rhodotorula
mucilaginosa, and Debaryomyces spp. showed little variation per species per drug, as typical for
the clinical azoles, large variation in particular was seen within Bullera alba isolates toward
difenoconazole. Isolates of B. alba from the control (n=3), low treatment (n=3), and high treatment
(n=3) plots produced average zones of inhibition to difenoconazole at 43.0 ± 4.6 mm, 33.7 ± 15.5
mm, and 29.3 ± 6.0 mm, respectively.
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Figure 14 – Sensitivity of Cyberlindnera saturnus Isolates to Triazoles
No significant difference in average ZOI was noted in tests using yeasts from the control versus
treated plots.
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4

Discussion

4.1 Impact of fungicide exposure on population dynamics
As shown by the plate counts on RB agar, the lower number of recovered colonies per gram of soil
plated between the soils from the control versus the high treatment suggests that the clotrimazole
and miconazole in the high treatment plots led to lower viable fungal propagules (Figure 8). The
fact that the high treatment soils sampled in 2018 had lower ergosterol content per gram of soil
than the samples from the control plots further shows that the high treatment soils have reduced
fungal load due to the long-term effects of the antifungal drugs in the soil (Figure 9). The increase
in ergosterol content seen in the control soils versus the high treatment soils sampled in 2018 may
have been due to increased fungal growth in the rhizosphere of the cropped soybeans over eight
years (Figure 9).

The RB and DG agars contain rose bengal and dichloran, respectively, which inhibit the radial
growth of fungi that can spread over large portions of the plate in a species-dependent manner
(King et al., 1979). This leads to higher colony counts and the effective isolation of slowergrowing species (Henson, 1981; Hocking & Pitt, 1980; King et al., 1979). In addition, incubation
at 4℃ selects for yeasts, especially psychrophilic yeasts, over filamentous fungi, and the addition
of 220 g/L glycerol in the DG agar selects for xerophilic species. One possible reason why the
colony counts on DG agar did not show a significant difference between treated and untreated soils
is due to the sporulation of filamentous fungi after the six week incubation period. Nonetheless,
the RB plates incubated at 15℃ for four days were almost exclusively dominated by filamentous
fungi growth while still showing significant differences in colony counts between the control
versus high treatment soils.

The observation that both the yeasts and filamentous fungi collections from the control plots
showed lower diversity in the control plots versus the treated plots can be attributed to the fact that
several species were isolated only from the control plots but not the treated plots. Several yeasts,
amounting to 13.7% of the collection, were identified as belonging to species isolated only once
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(Table 2). Half of these unique isolates were isolated from the control plots while the remaining
half were isolated evenly between the low treatment and high treatment plots. In addition,
five Mrakia spp., and four isolates each of Cystofilobasidium infirmominiatum and Rhodotorula
graminis were isolated from the control and low treatment plots, but not the high treatment plots.
Likewise, for the filamentous fungi collection, 16.4% of identified isolates (12 of 73 isolates)
belonged to species represented only once in the dataset with half of these species being isolated
from the control plots (Table 3).

For

the

yeast

collections

respectively, Cyberlindnera
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the
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20%
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high

27%
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treatment
the
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while Rhodotorula mucilaginosa comprised 32% and 25%. However, it should be noted that the
fungal collections were constructed with the goals of maximizing diversity in the collections and
minimizing clonality. In particular, when broths enriched for yeasts were plated onto agar, if
colonies with identical morphologies were observed on the same agar plate, only one isolate was
retained for the collection. In addition, if more than one identical colony of a filamentous fungi
were growing on the same agar plate plated with soil, only one colony was retained for the
collection. Thus, it is not possible to easily determine from the fungal libraries if species that were
readily culturable are more or less represented in the control or treated soils as the enrichment
process would distort counts of yeasts. Nonetheless, although yeasts were not tallied by
morphology noted per agar plate, in certain instances, when each soil was directly plated onto agar,
it was clear that colonies of certain morphologies were less prevalent on plates containing high
treatment soils compared to control soils. For example, red pigmented colonies were observed on
all four DG agar plates plated with control soil on but were not observed on any of the four plates
plated with high treatment soil. A sampling of these red pigmented colonies identified two as
Rhodotorula.
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4.2 No evidence of increased azole resistance in isolates
from azole-containing soil
As shown by the disk diffusion assays, in general, yeasts and filamentous fungi isolated from the
soils receiving clotrimazole and miconazole were not detected to be any more or less sensitive to
the tested azoles when compared to isolates from the control plots. This pattern held when looking
at all isolated yeasts or filamentous fungi from a soil treatment type and when looking at specific
species, such as the yeast Cyberlindnera saturnus and Rhodotorula mucilaginosa and the
filamentous fungi Clonostachys rosea and Rhizomucor variabilis. However, some statistical tests
did show significant differences in sensitivities between sensitive isolates from different
treatments, as determined by smaller average zones of inhibition. For example, in the case of
difenoconazole, isolates from the low treatment appear to be more resistant to those from the
control with an average zone of inhibition nearly 10 mm smaller (p=0.0004) while the isolates
from the high treatment were not any more resistant (p=0.11). It could be argued that these pvalues are affected by low statistical power of the tests, as the average zone of inhibition from the
low treatment isolates was 34.3 ± 9.5 mm versus 42.4 ± 9.9 mm for the isolates from the control,
which puts the two averages within the 20% error range for ZOI measurements (Table 4.0; Table
6).

4.3 Susceptibilities of tested species versus literature values
Similar to the results from this study showing all R. mucilaginosa isolates being sensitive to
clotrimazole, an analysis of 72 strains of Rhodotorula–including five strains of R. mucilaginosa–
from hospitals in Iran (Seifi et al., 2013) in addition to five R. mucilaginosa strains from pigeon
feces in Saudi Arabia (Abulreesh et al., 2019) showed all R. mucilaginosa strains being sensitive
to clotrimazole. In this study, 80.5% of Rhodotorula isolates were considered to be weakly
susceptible to the miconazole disks, with an additional 17% being considered resistant and a single
isolate being classified as sensitive. Likewise, a study of 30 clinical Rhodotorula strains–21 of
them being R. mucilaginosa—from French hospitals found that miconazole was the only drug of
eight tested drugs showing a range of sensitivities, with most isolates being marked as
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‘intermediate’ (Preney et al., 2003). The clinical strains from Iran also showed a range of
sensitivities to miconazole, especially with R. mucilaginosa (Seifi et al., 2013).

In comparison to the relatively few Rhodotorula isolates tested to the medical imidazoles in the
literature, much more information exists on the sensitivity of clinical Rhodotorula isolates to the
medical triazoles. A review of 131 Rhodotorula isolates tested using the established NCCLS and
EUCAST methods, in addition to the commercially-available agar-based Etest and the microbroth
dilution-based Sensititre YeastOne tests, concluded that fluconazole, voriconazole, and
itraconazole were inactive against the majority of tested isolates (Gomez-Lopez et al., 2005). The
MIC90 values for 29 isolates tested by the reviewers were found to be >64, 8, and 8 mg/L to
fluconazole, itraconazole, and voriconazole, respectively. This is in accordance with this study,
which ultimately classified all Rhodotorula isolates as resistant to fluconazole, 85.4% of isolates
being resistant to voriconazole with the remaining being weakly susceptible, and 78% of isolates
being resistant to itraconazole with 14.6% being weakly susceptible and 7.3% being susceptible.

Nonetheless, previous studies have noted several differences between clinical and nonclinical Rhodotorula strains. For example, while clinical Rhodotorula strains are frequently noted
as fluconazole-resistant (Tuon & Costa, 2008), the Rhodotorula strains from pigeon feces in Saudi
Arabia were noted for their susceptibility to fluconazole (Abulreesh et al., 2019), a result shared
with five Rhodotorula strains isolated from bird feces in Malaysia (Lord et al., 2010). In addition,
a sample of clinical isolates was shown to have greater biofilm capacity compared to
environmental isolates (Nunes et al., 2013). As for sensitivity to agricultural azoles, a
metagenomic study of pear fruit fields treated with various fungicides, including azoles such as
difenoconazole and tebuconazole, found that the proportion of Rhodotorula isolates, primarily
represented by R. glutinis, increased in the fungicide-treated fields compared to control fields,
which suggests relative resistance to these drugs (Zambounis et al., 2020).

As for isolated filamentous fungi, Actinomucor elegans, Mortierella alpina, Mucor circinelloides,
and Rhizomucor variabilis were isolated from the soils and were expected to be resistant to the
azole drugs. These species belong to the Mucoromycotina order, which causes the highly-lethal
disease Mucormycosis (Jeong et al., 2019). A single amino acid change in residue 129 of CYP51
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F5 confers resistance to certain azoles, such as voriconazole and fluconazole, but not others, such
as itraconazole (Caramalho et al., 2017). The mechanism of resistance to the former drugs and
sensitivity to itraconazole has been elucidated to involve a tertiary hydroxyl group that interferes
with hydrogen bonding between the azole drug and the lanosterol 14a-demethylase enzyme
(Sagatova et al., 2016). Sun et al. reported that MIC values, as determined by CLSI microbroth
dilutions, for seven clinical Mucor sp. were all above 64 μg/mL for fluconazole and ranged
between 32-64 μg/mL for voriconazole (Sun et al., 2002). Meanwhile, the MIC values toward
itraconazole ranged from 0.25-8 μg/mL (Sun et al., 2002).

As expected, given the data from the literature, isolated Mucor circinelloides (n=2)
and Rhizomucor variabilis (n=9) were resistant to fluconazole and voriconazole and weakly
susceptible to miconazole and itraconazole. Interestingly, however, the isolates were clearly
susceptible to clotrimazole. In a preliminary test, a single tested M. circinelloides isolate from the
high treatment plots showed sensitivity to difenoconazole and tebuconazole and resistance to
propiconazole. This finding could be useful as Mucor rot has been described as an emerging
postharvest disease caused by Mucor spp. affecting multiple crops, such as mandarin oranges in
California (Saito et al., 2014). Resistance of the species Mucor rouxii to propiconazole has
previously been described (Weete & Wise, 1987).

4.4 Spectrums of activity and co-resistance between azoles
A previous study analyzed the antifungal susceptibility of 1,698 yeasts from various sources
(Desnos-Ollivier et al., 2012). The study defined isolates with a high MIC as being able to grow
in ≥8 ug/mL fluconazole, ≥0.25 ug/mL voriconazole, and ≥0.5 ug/mL of itraconazole.
Fluconazole was effective against the smallest proportion of environmental isolates, with 45%
having a high MIC toward the drug, while only 18-21% of environmental isolates had a high
MIC against voriconazole or itraconazole. The study also made the surprise finding that, when
considering isolates from all origins, which included isolation from human, food, and industrial
sources, Basidiomycetes were more likely to yield a high MIC to the three drugs than
Ascomycetes with high MIC rates of 75-76% compared to 16-34% (Desnos-Ollivier et al.,
2012).
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In agreement with the study, as shown in Figure 12.0, a higher proportion of isolates were
resistant to fluconazole than the other two tested medical triazoles. In addition, of the tested
medical imidazoles, clotrimazole was effective against a larger proportion of isolates compared
to miconazole, which agrees with a previous study of yeasts with medical significance
(Yamaguchi et al., 1983). When broken down by phylogeny, 82 Basidiomycete yeasts strains
were tested against the medical azoles with 8.5% and 26.8% being resistant to the imidazoles
clotrimazole and miconazole, respectively, and 15.8%, 69.5%, and 95.1% being resistant to the
triazoles itraconazole, voriconazole, and fluconazole, respectively. On the other hand, of 63
Ascomycete yeasts, all were susceptible to the medical azoles with the exception of two isolates
of Debaryomyces to fluconazole. All isolated filamentous fungi, except for the Mucormycetes,
belonged to the Ascomycota.

One unexpected finding from the azole sensitivity tests was that co-resistance to clotrimazole and
miconazole was not widely noted either in isolates obtained from the control plots or from the
plots receiving annual applications of clotrimazole and miconazole (Table 5.0; Supplementary
Table 3.9). Of the seven clotrimazole-resistant yeasts, one isolate identified as Filobasidium
oeirense and four isolates identified as Tausonia pullulans were sensitive to miconazole while two
isolates identified as Bullera alba were resistant to both drugs. On the other hand, most isolates
of Sampaiozyma ingeniosa were miconazole-resistant and only weakly susceptible to clotrimazole
while Rhodotorula mucilaginosa isolates were commonly miconazole-resistant while being
clearly susceptible to clotrimazole. With respect to filamentous fungi, the fact that the tested
Mucormycetes were sensitive to clotrimazole but not the other tested azole drugs lends further
evidence that the spectrum of activity of clotrimazole is significantly different from that of the
other clinical azoles. Overall, it was clear that, miconazole-resistant isolates were not likely to be
clotrimazole-resistant and clotrimazole-resistant isolates were not likely to be miconazoleresistant.
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4.5 Isolates with little prior azole documentation
As for the identified isolates determined to be very susceptible to miconazole, the azolesusceptibilities of the corresponding species have not been well-described in the literature. There
were no previous reports of the susceptibility of Sampaiozyma ingeniosa to the tested azoles
and Cutaneotrichosporon

terricola, Schwanniomyces

occidentalis, Solicoccozyma

aeria,

and Mrakia spp. to any azole in the literature. Of note, the disk diffusion assays were performed
at either 15°C or 30°C, while previous studies of environmental antifungal resistance tend to focus
on yeasts with medical or agricultural significance or those that can grow readily during testing.
For example, Maciel et al. did not test the azole susceptibility of Cutaneotrichosporon
terricola due to its inability to grow at 37°C (Maciel et al., 2019), and the disk diffusion assay
performed by Perini et al. where Mrakia spp. isolates were grown on SD agar for four days and
then tested on RPMI-glucose agar at 15°C for 2-7 days failed due to a lack of growth on test plates
(Perini et al., 2019). However, in this study, growing Mrakia isolates for seven days on SD agar
and then performing a four-day disk diffusion assay on RPMI-glucose agar plates, both at 15°C,
successfully allowed for azole susceptibility testing of 4 out of 6 Mrakia isolates.

On the other hand, a previous mycobiome sequencing study of the wheat phyllosphere mycobiome
after application of Viverda, an agricultural fungicide containing epoxiconazole in addition to
fungicides from other classes, identified V. victoriae as being the most susceptible species to the
effects of the fungicide (Knorr et al., 2019). Disk diffusion assays using the difenoconazole,
propiconazole, and tebuconazole disks on the same plate failed twice with indications of large
zones of inhibition only appearing after six-days of incubation. The findings from this study, as
well as the findings from the disk diffusion assay, indicate that this species may be hyper
susceptible to azoles.

A literature review yielded few results on the antifungal susceptibility of several other species
isolated and tested in this study. For example, the sole reference for the antifungal susceptibility
of C. saturnus comes from a single isolate obtained from Piracicaba River, Brazil that was tested
against a panel of drugs, including fluconazole and itraconazole, using a broth microdilution test
at 37℃ for 48 hours. The test yielded MIC80 values for fluconazole (>64 µg/mL) and itraconazole
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(0.25 µg/mL) marking relative resistance and susceptibility to the drugs, respectively, similar to
the results obtained in this study (Medeiros et al., 2008). However, when tested by disk diffusion
assays, C. saturnus isolates showed trailing endpoints toward all tested azole drugs and continued
growth within the zones of inhibition following the standard disk diffusion assay. Thus, C.
saturnus may be more resistant to azole drugs than suggested by both studies. The azole
susceptibility of C. saturnus may be of future interest due to its previously described abundance
in soils and ability to promote plant growth.

4.6 Isolates with human pathogenic potential
A previous analysis of 5,000 yeasts from 1,000 environmental samples yielded 54 strains of
budding yeasts with human pathogenic potential and found that pathogenic yeasts were associated
with soils compared to other sampling locations such as fruit, leaves, and wood (Opulente et al.,
2019). This study, on the other hand, yielded relatively more isolates classified as opportunistic
human pathogens including yeasts, such as Rhodotorula mucilaginosa, that are not classified as
‘budding yeast'.

Debaryomyces hansenii and Rhodotorula mucilaginosa are two opportunistic human pathogens
that are commonly isolated from environmental sources. D. hansenii (syn. Candida famata) is
particularly associated with dairy products as well as being a cause of infections of the
bloodstream, peritoneum, retina, and tissue of the mid-chest (reviewed in Beyda et al., 2013). The
ARTEMIS

global

antifungal

surveillance

program

found

that

of

over

250,000

clinical Candida isolates collected globally between 1997 and 2007, 0.3% were identified
as Candida famata (Pfaller et al., 2010). In addition, C. famata was isolated from 2.1% of 642
blood samples producing fungal isolates at Teikyo University Hospital, Japan between 1979 and
1995 (Kawakami et al. 1980). Although being a rare cause of infections, at least one case of
invasive infection has been detected in a patient with no underlying conditions or risk factors
(Wong et al., 1982). On the other hand, clinical infection of D. hansenii may be subject to
overestimation due to misidentification of Pichia guilliermondii (syn. Candida guilliermondii) as
D. hansenii (Desnos-Ollivier et al., 2008).
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Another candidiasis-causing yeast, Diutina catenulata (syn. Candida catenulata) was isolated
from a control plot. The species is commonly isolated from environmental samples, particularly
dairy products, and is a rare cause of invasive infections in immunocompromised hosts
(Radosavljevic et al., 1999).

Rhodoturla mucilaginosa has been described as an emerging opportunistic pathogen (Pfaller &
Diekema,

2004;

Wirth

&

Goldani,

2012).

As

reviewed

by

Wirth

&

Goldani

(2012), Rhodotorula species are ubiquitous in the environment, having been isolated from
environmental samples, such as air, soil, and food products, as well as being detected as the most
common microorganism from the hands of hospital workers. R. mucilaginosa is also a common
contaminant of catheters due to its strong affinity for plastic. It follows that most cases of infections
involve central venous catheter (CVC) use and, most likely due to the increase in CVC use, reports
of infections have increased in haematological patients since 1985. Infections can also, especially
in HIV-positive patients, lead to serious complications such as meningitis and endophthalmitis
(Wirth & Goldani, 2012). Overall, Rhodotorula was found in 4.2% of clinical isolates (n=8821) in
the ARTEMIS project, being the 4th-most common non-Candida yeast (Pfaller, Diekema, et al.,
2009).

No other yeasts of clinical relevance was identified in the collection. Although some case studies
note Tausonia pullulans (syn. Trichosporon pullulans) as a cause of trichosporonosis in
immunocompromised hosts, reports of T. pullulans infections may be due to misidentification
(Holland et al., 2004).

For filamentous fungi, the most clinically relevant group isolated from the soils
was Aspergillus spp., which cause a group of diseases called aspergillosis. Aspergillosis can
present as respiratory infections as spores of the fungi are introduced into the lungs. Patients with
asthma or cystic fibrosis can suffer from allergic bronchopulmonary aspergillosis, which is an
allergic reaction to the fungi that can damage lung tissue (Latgé, 1999). In addition, those with
pre-existing lung conditions can suffer from aspergilloma, balls of the fungi in the lungs, which
are commonly asymptomatic but can also lead to fatal internal bleeding due to disrupted blood
vessels (Latgé, 1999). In addition, aspergillosis can present as an invasive infection in
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immunocompromised patients with severity and symptoms depending on the organ infected and
the underlying condition (Latgé, 1999).

In addition, Purpureocillium lilacinum has been noted for causing invasive infections in
immunocompromised patients. The fungus can spread quite readily, for example, in contaminated
lotion in a hospital (Orth, 1996). Spores of the species are used in the agricultural setting as a
biocontrol agent where it has been suggested that they pose a risk to immunocompromised people
(Luangsa-Ard et al., 2011). The species can cause serious eye infections, such as keratitis and
endophthalmitis, in those who wear soft contact lenses or have trauma to the eyes (Todokoro et al.
2014) and can also cause dermatological infections without predisposing conditions (Saghrouni et
al., 2013).

Fusarium species are found in environmental samples, such as soil and air, and are opportunistic
human pathogens. For immunocompetent people, Fusarium infections can cause onychomycosis
in those that walk outdoors with exposed toenails, cutaneous infections for burn victims, and
keratitis for contact lens users. On the other hand, in cancer patients, those with severe burns, or
organ transplant patients, skin, lung, and sinus infections can develop (Dignani & Anaissie, 2004).
In institutions monitoring severely immunocompromised patients, such as cancer patients and
marrow transplants, Fusarium infections were documented at incidences of around 0.2-1.2% of
patients (Dignani & Anaissie, 2004).

Other isolated filamentous fungi have been identified as the causative agent of an infection only
recently. For the first time, in 2017, Chowdhary et al. reported Penicillium oxalicum as the cause
of invasive infections in three cases involving immunocompromised patients (Chowdhary et al.,
2017). In addition, for the first time, in 2020, Masetti et al. reported Albifimbria verrucaria as the
causative agent of an invasive infection in human, a child with neuroblastoma (Masetti et al.,
2020).
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4.7 Isolates with notable agricultural relevance
The two most commonly isolated yeasts from the soils, Cyberlindnera saturnus and Rhodotorula
mucilaginosa, have previously been studied for their association with crops, especially with
respect to their ability to promote plant growth. The first report of an auxin-producing endophytic
yeasts was for an isolate of Cyberlindnera saturnus (syn. Williopsis saturnus). This endophyte of
maize roots was found to produce the plant growth promoting hormones indole-3-acetic acid and
indole-3-pyruvic acid in vitro and increase root and shoot growth of maize following seedling
inoculation (Nassar et al., 2005). Isolates of R. mucilaginosa have been found to be endophytes of
cottonwood and produce indole-3-acetic acid (Xin et al., 2009).

Compared to the isolated yeasts, the isolated filamentous fungi strains have been documented more
thoroughly for agricultural relevance, where they range from pathogenic to growth-promoting. For
example, species in the Fusarium solani complex are a cause of sudden death syndrome of
soybeans in North America (Aoki et al., 2003), while those in the F. oxysporum complex can cause
root rot and seedling blight (Lanubile et al., 2015). On the other hand, it has been shown that
inoculation of seeds and subsequent colonization of maize plants with Metarhizium robertsii leads
to higher above-ground biomass, suppression of growth of black cutworm larvae on leaves, and
alteration expression of plant defense genes (Ahmad et al., 2020). Strains of Clonostachys
rosea have been reported to cause root rot in soybeans (Bienapfl et al., 2012) while strains have
also been positively associated with suppression of Sclerotinia sclerotiorum, the fungal pathogen
causing white mould, and increased shoot length upon inoculation (Rodríguez et al., 2015).

4.8 Future experiments and closing remarks
Given the number of filamentous fungi recovered with medical and agricultural significance,
future experiments can test the recovered filamentous fungi to medical triazoles and agricultural
triazoles. In addition, while initial colony counts were performed on agar containing 1 mg/L
clotrimazole and 1 mg/L miconazole, little growth was observed on plates (Figure 10). Thus, future
experiments can plate the treated and untreated soils on agars containing various lower
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concentrations of the drugs to obtain suitable plate counts. These plate counts can be used to see
if the treated soils contain more azole-resistant isolates than the untreated soils. In addition, replica
plating from agar containing no azole drugs to agar containing miconazole can be used to further
test the hypothesis that the control soils contain more isolates that are highly susceptible to
miconazole. Finally, in order to see if any particular species shows differential abundance between
the control and treated soils, targeted plate counts could be used. For example, Debaryomyces
hansenii isolates can be selectively grown in conditions of 5% glucose and 10% NaCl (Breuer &
Harms, 2006) and Rhodotorula species can be readily identified by pink-red colonies on SD agar.
In addition, qPCR assays can also be used. Assays have already been published for
quantifying Cystofilobasidium infirmominiatum (Spotts et al., 2009), a yeast isolated from the
control and low treatment plots but not the high treatment plots, and Vishniacozyma
victoriae (Rush et al., 2020), a yeast found to be highly susceptible to miconazole and the
agricultural fungicide Vividera. In addition, assays for quantifying the medically and agriculturally
important filamentous fungi Mucor circinelloides and Clonostachys rosea also exist (BernalMartinez et al.; Gimeno et al., 2019). Microbial community profiling using next-generation
sequencing techniques can also further elucidate changes in community composition between the
treated and untreated soils.

Overall, it was found that soils amended with environmentally-relevant concentrations of
miconazole and clotrimazole showed reduced fungal load and diversity compared to control soils.
While notable changes in azole susceptibility were not detected among the fungal isolates from
the treated versus control soils, there was some indication that the treated soils contained fewer
isolates highly susceptible to miconazole. Given the isolation of medically and agriculturally
important fungi, future studies on the impact of azole contamination of soils is justified.

65

5

Literature Cited

Abulreesh, H. H., Organji, S. R., Elbanna, K., Osman, G. E., Almalki, M. H., Abdel-Malek,
A. Y., Ghyathuddin, A. A. K., Ahmad, I. (2019). Diversity, virulence factors, and
antifungal susceptibility patterns of pathogenic and opportunistic yeast species in rock
pigeon (Columba livia) fecal droppings in Western Saudi Arabia. Polish Journal of
Microbiology 68, 493–504.
Agency for Healthcare Research and Quality. (2018). Number of people with purchase in
thousands by prescribed drug, United States, 1996-2018. Medical Expenditure Panel
Survey, Agency for Healthcare Research and Quality, U.S. Department of Health and
Human

Services,

Rockville,

MD.

Retrieved

from

https://meps.ahrq.gov/mepstrends/hc_pmed/.
Ahmad, I., del Mar Jiménez-Gasco, M., Luthe, D. S., Shakeel, S. N., & Barbercheck, M. E.
(2020). Endophytic Metarhizium robertsii promotes maize growth, suppresses insect
growth, and alters plant defense gene expression. Biological Control 144, 104167.
Aljohani, R., Samarasinghe, H., Ashu, T., & Xu, J. (2018). Diversity and relationships among
strains of culturable yeasts in agricultural soils in Cameroon. Scientific Reports 8, 1–11.
Altschul, S. F., Gish, W., Miller, W., Myers, E. W., & Lipman, D. J. (1990). Basic local
alignment search tool. Journal of Molecular Biology 215, 403–410.
Anderson, J. B. (2005). Evolution of antifungal-drug resistance: Mechanisms and pathogen
fitness. Nature Reviews Microbiology 3, 547–556.
Aoki, T., O'Donnell, K., Homma, Y., & Lattanzi, A. R. (2003). Sudden-death syndrome of
soybean is caused by two morphologically and phylogenetically distinct species within
the Fusarium solani species complex—F. virguliforme in North America and F.
tucumaniae in South America. Mycologia, 95, 660-684.
Bensasson, D., Dicks, J., Ludwig, J. M., Bond, C. J., Elliston, A., Roberts, I. N., & James,
S. A. (2019). Diverse lineages of Candida albicans live on old oaks. Genetics 211, 277–
288.
Bernal-Martinez, L., Buitrago, M. J., Castelli, M. V., Rodriguez-Tudela, J. L., CuencaEstrella, M. (2013). Development of a single tube multiplex real-time PCR to detect the

66
most clinically relevant Mucormycetes species. Clinical Microbiology and Infection 19,
E1-E7.
Beyda, N. D., Chuang, S. H., Jahangir Alam, M., Shah, D. N., Ng, T. M., McCaskey, L., &
Garey, K. W. (2013). Treatment of Candida famata bloodstream infections: Case series
and review of the literature. Journal of Antimicrobial Chemotherapy 68, 438–443.
Bienapfl, J. C., Floyd, C. M., Percich, J. A., & Malvick, D. K. (2012). First report of
Clonostachys rosea causing root rot of soybean in the United States. Plant Disease 96,
1700-1700.
Birkhofer, K., Schöning, I., Alt, F., Herold, N., Klarner, B., Maraun, M., … Schrumpf, M.
(2012). General relationships between abiotic soil properties and soil biota across spatial
scales and different land-use types. PLoS One 7, e43292.
Bowyer, P., & Denning, D. W. (2014). Environmental fungicides and triazole resistance in
Aspergillus. Pest Management Science 70, 173–178.
Breuer, U., & Harms, H. (2006). Debaryomyces hansenii - an extremophilic yeast with
biotechnological potential. Yeast 23, 415–437.
Camps, S. M. T., Rijs, A. J. M. M., Klaassen, C. H. W., Meis, J. F., O’Gorman, C. M., Dyer,
P. S., Melchers, W. J. G., Verweij, P. E. (2012). Molecular epidemiology of Aspergillus
fumigatus isolates harboring the TR34/L98H azole resistance mechanism. Journal of
Clinical Microbiology 50, 2674–2680.
Cao, D., Wu, R., Dong, S., Wang, F., Ju, C., Yu, S., Xhu, S., Fang, H., Yu, Y. (2020). Triazole
resistance in Aspergillus fumigatus in crop plant soil after tebuconazole applications.
Environmental Pollution 266, 115–124.
Caramalho, R., Tyndall, J. D. A., Monk, B. C., Larentis, T., Lass-Flörl, C., & Lackner, M.
(2017). Intrinsic short-tailed azole resistance in Mucormycetes is due to an evolutionary
conserved amino acid substitution of the lanosterol 14α-demethylase. Scientific Reports
7, 15898.
Casadevall, A., Kontoyiannis, D. P., & Robert, V. (2019). On the emergence of Candida auris:
climate change, azoles, swamps, and birds. MBio 10, e01397-19.
CDC. (2019). Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S.
Department of Health and Human Services, Centre for Disease Control and Prevention.

67
Chamberlain, S. A., & Szöcs, E. (2013). Taxize: taxonomic search and retrieval in R.
F1000Research 2, 191.
Chen, P. Y., Chuang, Y. C., Wu, U. I., Sun, H. Y., Wang, J. T., Sheng, W. H., Lo, H. J.,
Wang, H. Y., Chen, Y.C., Chang, S. C. (2019). Clonality of fluconazole-nonsusceptible
Candida tropicalis in bloodstream infections, Taiwan, 2011-2017. Emerging Infectious
Diseases 25, 1668–1675.
Chen, Z. F., Ying, G. G., Ma, Y. B., Lai, H. J., Chen, F., & Pan, C. G. (2013). Occurrence
and dissipation of three azole biocides climbazole, clotrimazole and miconazole in
biosolid-amended soils. Science of the Total Environment 452, 377–383.
Chowdhary, A., Kathuria, S., Agarwal, K., Sachdeva, N., Singh, P. K., Jain, S., & Meis, J.
F. (2017). Voriconazole-resistant Penicillium oxalicum: An emerging pathogen in
immunocompromised hosts. Open Forum Infectious Diseases 1, ofu029.
Chowdhary, A., Kathuria, S., Xu, J., & Meis, J. F. (2013). Emergence of azole-resistant
Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to
human health. PLoS Pathogens 9, e1003633.
CLSI. (2008a). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts;
Approved Standard—Third Edition. CLSI document M27-A3. Wayne, PA: Clinical and
Laboratory Standards Institute.
CLSI. (2008b). Reference Method for Broth Dilution Antifungal Susceptibility Testing of
Filamentous Fungi; Approved Standard—Second Edition. CLSI document M38-A2.
Wayne, PA: Clinical and Laboratory Standards Institute.
CLSI. (2009). Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts; Approved
Guideline—Second Edition. CLSI document M44-A2. Clinical and Laboratory Standards
Institute, Wayne, P.A.
CLSI. (2010). Method for Antifungal Disk Diffusion Susceptibility Testing of Nondermatophyte
Filamentous Fungi; Approved Guideline. CLSI document M51-A. Clinical and
Laboratory Standards Institute, Wayne, P.A.
Desnos-Ollivier, M., Ragon, M., Robert, V., Raoux, D., Gantier, J. C., & Dromer, F. (2008).
Debaryomyces hansenii (Candida famata), a rare human fungal pathogen often
misidentified as Pichia guilliermondii (Candida guilliermondii). Journal of Clinical
Microbiology 46, 3237–3242.

68
Desnos-Ollivier, M., Robert, V., Raoux-Barbot, D., Groenewald, M., & Dromer, F. (2012).
Antifungal susceptibility profiles of 1698 yeast reference strains revealing potential
emerging human pathogens. PLoS One 7, e32278.
Dignani, M. C., & Anaissie, E. (2004). Human fusariosis. Clinical Microbiology and Infection
10, 67–75.
Dixon, D. M., & Walsh, T. J. (1996). Chapter 76: antifungal agents. Medical microbiology, 4th
ed, edited by Samuel Baron. University of Texas Medical Branch at Galveston,
Galveston, TX.
Djajakirana, G., Joergensen, R. G., & Meyer, B. (1996). Ergosterol and microbial biomass
relationship in soil. Biology and Fertility of Soils 22, 299–304.
Douglass, A. P., Offei, B., Braun-Galleani, S., Coughlan, A. Y., Martos, A. A. R., OrtizMerino, R. A., Byrne, K. P., & Wolfe, K. H. (2018). Population genomics shows no
distinction between pathogenic Candida krusei and environmental Pichia kudriavzevii:
one species, four names. PLoS Pathogens 14, e1007138.
Ester, A. B. M., & Hoeprich, P. D. (1976). Effect of culture media on the antifungal activity of
miconazole and amphotericin B methyl ester. The Journal of Infectious Diseases 134,
336–341.
EUCAST. (2015). Method for the determination of broth dilution minimum inhibitory
concentrations of antifungal agents for conidia forming moulds. EUCAST document
E.DEF9.3.1. The European Committee on Antimicrobial Susceptibility Testing, Basel,
Switzerland.
EUCAST. (2020). Method for the determination of broth dilution minimum inhibitory
concentrations of antifungal agents for yeasts. EUCAST document E.DEF7.3.2. The
European Committee on Antimicrobial Susceptibility Testing, Basel, Switzerland.
Fisher, M. C., Hawkins, N. J., Sanglard, D., & Gurr, S. J. (2018). Worldwide emergence of
resistance to antifungal drugs challenges human health and food security. Science 360,
739–742.
García-Valcárcel, A. I., & Tadeo, J. L. (2012). Influence of moisture on the availability and
persistence of clotrimazole and fluconazole in sludge-amended soil. Environmental
Toxicology and Chemistry 31, 501–507.

69
Gardes, M., & Bruns, T.D. (1993). ITS primers with enhanced specificity for basidiomycetes‐
application to the identification of mycorrhizae and rusts. Molecular Ecology 2, 113-118.
Gimeno, A., Sohlberg, E., Pakula, T., Keller, B., Laitila, A., & Vogelgsang, S. (2019).
TaqMan qPCR for quantification of Clonostachys rosea used as a biological control
agent against Fusarium graminearum. Frontiers in Microbiology 10, 1627.
Gomez-Lopez, A., Mellado, E., Rodriguez-Tudela, J. L., & Cuenca-Estrella, M. (2005).
Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review.
Journal of Antimicrobial Chemotherapy 55, 312–316.
Gottschall, N., Topp, E., Metcalfe, C., Edwards, M., Payne, M., Kleywegt, S., Russel, P.,
Lapen, D. R. (2012). Pharmaceutical and personal care products in groundwater,
subsurface drainage, soil, and wheat grain, following a high single application of
municipal biosolids to a field. Chemosphere 87, 194–203.
Government of Ontario. (2002). Ontario Regulation 267/03, Nutrient Management Act, 2002.
Griffiths, C., & Brock, A. (2003). Twentieth century mortality trends in England and Wales.
Health Statistics Quarterly 18, 5-17
Henson, O. E. (1981). Dichloran as an inhibitor of mold spreading in fungal plating media:
Effects on colony diameter and enumeration. Applied and Environmental Microbiology
42, 656–660.
Hocking, A. D., & Pitt, J. I. (1980). Dichloran-glycerol medium for enumeration of xerophilic
fungi from low-moisture foods. Applied and Environmental Microbiology 39, 488–492.
Holland, S. M., Shea, Y. R., & Kwon-Chung, J. (2004). Regarding “Trichosporon pullulans
infection in 2 patients with chronic granulomatous disease.” Journal of Allergy and
Clinical Immunology 114, 205–206.
Jeong, W., Keighley, C., Wolfe, R., Lee, W. L., Slavin, M. A., Kong, D. C. M., & Chen, S.
C. A. (2019). The epidemiology and clinical manifestations of mucormycosis: a
systematic review and meta-analysis of case reports. Clinical Microbiology and Infection
25, 26–34.
Kawakami, S., Ono, Y., Miyazawa, Y., & Yamaguchi, H. (1980). Survey of fungemia cases
during the past seventeen years at Teikyo University Hospital. The Journal of the
Japanese Association for Infectious Diseases 72, 105–113.

70
Kim, J. S., Kim D.S., & Ko, S.H. (2017). Yeasts in internal roots of the rare plant Dendropanax
morbifera. Journal of the Korean Applied Science and Technology 34, 33–40.
Kim, J. S., & Kim, D. S. (2017). Endophytic yeasts colonize roots of Ulmus parvifolia Jacq.
and Quercus salicina Blume. Korean Journal of Environmental Agriculture 36, 135–
139.
King, A. D., Hocking, A. D., & Pitt, J. I. (1979). Dichloran-rose bengal medium for
enumeration and isolation of molds from foods. Applied and Environmental
Microbiology 37, 959–964.
Knorr, K., Jørgensen, L. N., & Nicolaisen, M. (2019). Fungicides have complex effects on the
wheat phyllosphere mycobiome. PLoS One 14, e0213176.
Köller, W., & Wubben, J. P. (1989). Variable resistance factors of fungicides acting as sterol
demethylation inhibitors. Pesticide Science 26, 133–145.
Lanubile, A., Muppirala, U. K., Severin, A. J., Marocco, A., & Munkvold, G. P. (2015).
Transcriptome profiling of soybean (Glycine max) roots challenged with pathogenic and
non-pathogenic isolates of Fusarium oxysporum. BMC genomics 16, 1-14.
Larkin, E. L., Ali, A. A. L., & Swindell, K. (2019). History of Antifungals. Antifungal Therapy,
2nd ed., edited by M. A. Ghannoum & J. R. Perfect. CBC Press, Taylor & Francis Group,
New York, N.Y.
Latgé, J. P. (1999). Aspergillus fumigatus and aspergillosis. Clinical Microbiology Reviews 12,
310–350.
Lavergne, R. A., Chouaki, T., Hagen, F., Toublanc, B., Dupont, H., Jounieaux, V., ... & Le
Pape, P. (2017). Home environment as a source of life-threatening azole-resistant
Aspergillus fumigatus in immunocompromised patients. Clinical Infectious Diseases 64,
76-78.
Leonardelli, F., Macedo, D., Dudiuk, C., Cabeza, M. S., Gamarra, S., & Garcia-Effron, G.
(2016). Aspergillus fumigatus intrinsic fluconazole resistance is due to the naturally
occurring T301I substitution in Cyp51Ap. Antimicrobial Agents and Chemotherapy 60,
5420–5426.
Lindberg, R. H., Fick, J., & Tysklind, M. (2010). Screening of antimycotics in Swedish
sewage treatment plants. Water Research 44, 649–657.

71
Lo, H. J., Tsai, S. H., Chu, W. L., Chen, Y. Z., Zhou, Z. L., Chen, H. F., Lee, C.F., Yang,
Y. L. (2017). Fruits as the vehicle of drug resistant pathogenic yeasts. Journal of
Infection 75, 254–262.
Lõoke, M., Kristjuhan, K., & Kristjuhan, A. (2011). Extraction of genomic DNA from yeasts
for PCR-based applications. BioTechniques 50, 325–328.
Lord, A. T. K., Mohandas, K., Somanath, S., & Ambu, S. (2010). Multidrug resistant yeasts
in synanthropic wild birds. Annals of Clinical Microbiology and Antimicrobials 9, article
11.
Luangsa-Ard, J., Houbraken, J., van Doorn, T., Hong, S. B., Borman, A. M., Hywel-Jones,
N. L., & Samson, R. A. (2011). Purpureocillium, a new genus for the medically
important Paecilomyces lilacinus. FEMS Microbiology Letters 321, 141–149.
Maciel, N. O. P., Johann, S., Brandão, L. R., Kucharíková, S., Morais, C. G., Oliveira, A.
P., Freitas, G. J. C., Borelli, B. M., Pellizzari, F. M., Santos, D. A., Dijck, P. V., Rosa,
C. A. (2019). Occurrence, antifungal susceptibility, and virulence factors of
opportunistic yeasts isolated from Brazilian beaches. Memórias Do Instituto Oswaldo
Cruz 114, e180566.
Masetti, R., Prodi, A., Liberatore, A., Carfagnini, F., Cappelletti, E., Leardini, D., Pession,
A., De Carolis, E., Cricca, M. (2020). Occurrence of Albifimbria verrucaria in the blood
of a female child with neuroblastoma. Frontiers in Medicine 7, 13.
Medeiros, A. O., Kohler, L. M., Hamdan, J. S., Missagia, B. S., Barbosa, F. A. R., & Rosa,
C. A. (2008). Diversity and antifungal susceptibility of yeasts from tropical freshwater
environments in Southeastern Brazil. Water Research 42, 3921–3929.
Mille-Lindblom, C., von Wachenfeldt, E., & Tranvik, L. J. (2004). Ergosterol as a measure
of living fungal biomass: persistence in environmental samples after fungal death.
Journal of Microbiological Methods 59, 253–262.
Montgomery, H. J., Monreal, C. M., Young, J. C., & Seifert, K. A. (2000). Determination of
soil fungal biomass from soil ergosterol analyses. Soil Biology and Biochemistry 32,
1207–1217.
Nassar, A. H., El-Tarabily, K. A., & Sivasithamparam, K. (2005). Promotion of plant growth
by an auxin-producing isolate of the yeast Williopsis saturnus endophytic in maize (Zea
mays L.) roots. Biology and Fertility of Soils 42, 97–108.

72
Nomura, K., Kawasugi, K., & Morimoto, T. (2006). Cost-effectiveness analysis of antifungal
treatment for patients on chemotherapy. European Journal of Cancer Care 15, 44–50.
Nunes, J. M., Bizerra, F. C., e Ferreira, R. C., & Colombo, A. L. (2013). Molecular
identification, antifungal susceptibility profile, and biofilm formation of clinical and
environmental Rhodotorula species isolates. Antimicrobial Agents and Chemotherapy
57, 382–389.
Opulente, D. A., Langdon, Q. K., Buh, K. V., Haase, M. A. B., Sylvester, K., Moriarty, R.
V., Jarzyna, M., Considine, S. L., Schneider, R. M., Hittinger, C. T. (2019).
Pathogenic budding yeasts isolated outside of clinical settings. FEMS Yeast Research 19,
foz032.
Orth, B., Frei, R., Itin, P. H., Rinaldi, M. G., Speck, B., Gratwohl, A., & Widmer, A. F.
(1996). Outbreak of invasive mycoses caused by Paecilomyces lilacinus from a
contaminated skin lotion. Annals of internal medicine 125, 799-806.
Pappas, P. G., Alexander, B. D., Andes, D. R., Hadley, S., Kauffman, C. A., Freifeld, A., ...
& Chiller, T. M. (2010). Invasive fungal infections among organ transplant recipients:
results of the Transplant-Associated Infection Surveillance Network (TRANSNET).
Clinical Infectious Diseases, 50, 1101-1111.
Pasanen, A.-L., Yli-Pietila, K., Pasanen, P., Kalliokoski, P., & Tarhanen, J. (1999).
Ergosterol content in various fungal species and biocontaminated building materials.
Applied and Environmental Microbiology 65, 138–142.
Peay, K. G., Kennedy, P. G., & Talbot, J. M. (2016). Dimensions of biodiversity in the Earth
mycobiome. Nature Reviews Microbiology 14, 434–447.
Perini, L., Mogrovejo, D. C., Tomazin, R., Gostinčar, C., Brill, F. H. H., & GundeCimerman, N. (2019). Phenotypes associated with pathogenicity: Their expression in
Arctic fungal isolates. Microorganisms 7, 600.
Pest Management Regulatory Agency. (2016a). Proposed Re-evaluation Decision,
Antisapstain and Joinery Uses of Propiconazole (PRVD2016-19). Pest Management
Regulatory Agency, Government of Canada, Ottawa, ON.
Pest Management Regulatory Agency. (2016b). Proposed Registration Decision,
Tebuconazole (PRD2016-33). Pest Management Regulatory Agency, Government of
Canada, Ottawa, ON.

73
Pest Management Regulatory Agency. (2016c). Registration Decision, Difenoconazole
(RD2016-07). Pest Management Regulatory Agency, Government of Canada, Ottawa,
ON.
Pfaller, M. A., & Diekema, D. J. (2004). Rare and emerging opportunistic fungal pathogens:
Concern for resistance beyond Candida albicans and Aspergillus fumigatus. Journal of
Clinical Microbiology 42, 4419–4431.
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Bijie, H., Dzierzanowska, D.,
Klimko, N. N., Letscher-Bru, V., Lisalova, M., Muehlethaler, K., Rennison, C.,
Zaidi, M., the Global Antifungal Surveillance Group. (2009). Results from the
ARTEMIS DISK global antifungal surveillance study, 1997 to 2007: 10.5-year analysis
of susceptibilities of noncandidal yeast species to fluconazole and voriconazole
determined by CLSI standardized disk diffusion testing. Journal of Clinical
Microbiology 47, 117–123.
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A.,
Ling, T. A., the Global Antifungal Surveillance Group. (2010). Results from the
ARTEMIS disk global antifungal surveillance study, 1997 to 2007: A 10.5-year analysis
of susceptibilities of Candida species to fluconazole and voriconazole as determined by
CLSI standardized disk diffusion. Journal of Clinical Microbiology 48, 1366–1377.
Pfaller, M. A., Messer, S. A., Bolmström, A., Odds, F. C., & Rex, J. H. (1996). Multisite
reproducibility of the Etest MIC method for antifungal susceptibility testing of yeast
isolates. Journal of Clinical Microbiology 34, 1691–1693.
Pfaller, M. A., Messer, S. A., Hollis, R. J., Boyken, L., Tendolkar, S., Kroeger, J., &
Diekema, D. J. (2009). Variation in susceptibility of bloodstream isolates of Candida
glabrata to fluconazole according to patient age and geographic location in the United
States in 2001 to 2007. Journal of Clinical Microbiology 47, 3185–3190.
Preney, L., Theraud, M., Guiguen, C., & Gangneux, J. (2003). Experimental evaluation of
antifungal and antiseptic agents against Rhodotorula spp. Mycoses 46, 492–495.
Radosavljevic, M., Koenig, H., Letscher-Bru, V., Waller, J., Maloisel, F., Lioure, B., &
Herbrecht, R. (1999). Candida catenulata fungemia in a cancer patient. Journal of
Clinical Microbiology 37, 475–477.

74
Rocha, M. F. G., Alencar, L. P., Paiva, M. A. N., Melo, L. M., Bandeira, S. P., Ponte, Y. B.,
… Brilhante, R. S. N. (2016). Cross-resistance to fluconazole induced by exposure to
the agricultural azole tetraconazole: An environmental resistance school? Mycoses 59,
281–290.
Rodríguez, M. A., Rothen, C., Lo, T. E., Cabrera, G. M., & Godeas, A. M. (2015).
Suppressive soil against Sclerotinia sclerotiorum as a source of potential biocontrol
agents: selection and evaluation of Clonostachys rosea BAFC1646. Biocontrol Science
and Technology 25, 1388-1409.
Rush, R., Cochran, S., Haines, S., Acosta, L., Divjan, A., Rundle, A., Miller, R.,
Perzanowski, M., Dannemiller, K., Green, B. (2020). Detection of environmentally
ubiquitous Vishniacozyma victoriae (syn. Cryptococcus victoriae) in the homes of
asthmatic and non-asthmatic children in New York City. Journal of Allergy and Clinical
Immunology 145, AB164.
Levy, S.B. (2002). Factors impacting on the problem of antibiotic resistance. Journal of
Antimicrobial Chemotherapy 49, 25–30.
Sabourin, L., Al-Rajab, A. J., Chapman, R., Lapen, D. R., & Topp, E. (2011). Fate of the
antifungal drug clotrimazole in agricultural soil. Environmental Toxicology and
Chemistry 30, 582–587.
Sabourin, L., Duenk, P., Bonte-Gelok, S., Payne, M., Lapen, D. R., & Topp, E. (2012).
Uptake of pharmaceuticals, hormones and parabens into vegetables grown in soil
fertilized with municipal biosolids. Science of the Total Environment 431, 233–236.
Sagatova, A. A., Keniya, M. V., Wilson, R. K., Sabherwal, M., Tyndall, J. D. A., & Monk,
B. C. (2016). Triazole resistance mediated by mutations of a conserved active site
tyrosine in fungal lanosterol 14α-demethylase. Scientific Reports 6, 1–11.
Saghrouni, F., Saidi, W., Ben Said, Z., Gheith, S., Ben Said, M., Ranque, S., & Denguezli,
M. (2013). Cutaneous hyalohyphomycosis caused by Purpureocillium lilacinum in an
immunocompetent patient: case report and review. Medical Mycology 51, 664–668.
Saito, S., Michailides, T., & Xiao, C. (2014). Mucor rot—An emerging postharvest disease of
mandarin fruit caused by Mucor piriformis and other Mucor spp. in California. Plant
Disease 100, 1054–1063.

75
Schoustra, S. E., Debets, A. J., Rijs, A. J., Zhang, J., Snelders, E., Leendertse, P. C., ... &
Verweij, P. E. (2019). Environmental hotspots for azole resistance selection of
Aspergillus fumigatus, the Netherlands. Emerging Infectious Diseases 25, 1347.
Seifi, Z., Mahmoudabadi, A. Z., & Hydrinia, S. (2013). Isolation, identification and
susceptibility profile of Rhodotorula species isolated from two educational hospitals in
Ahvaz. Jundishapur Journal of Microbiology 6, e8935.
Serfling, A., Wohlrab, J., & Deising, H. B. (2007). Treatment of a clinically relevant plantpathogenic fungus with an agricultural azole causes cross-resistance to medical azoles
and potentiates caspofungin efficacy. Antimicrobial Agents and Chemotherapy 51,
3672–3676.
Sláviková, E., & Vadkertiová, R. (2003). The diversity of yeasts in the agricultural soil.
Journal of Basic Microbiology 43, 430–436.
Snelders, E., Camps, S. M. T., Karawajczyk, A., Schaftenaar, G., Kema, G. H. J., van der
Lee, H. A., Klaassen, C. H., Melchers, W. J. G., Verweij, P. E. (2012). Triazole
fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus.
PLoS One, 7, e31801.
Snelders, E., Huis in’t Veld, R. A. G., Rijs, A. J. M. M., Kema, G. H. J., Melchers, W. J. G.,
& Verweij, P. E. (2009). Possible environmental origin of resistance of Aspergillus
fumigatus to medical triazoles. Applied and Environmental Microbiology 75, 4035–4057.
Sommermann, L., Geistlinger, J., Wibberg, D., Deubel, A., Zwanzig, J., Babin, D.,
Schluter, A., Schellenberg, I. (2018). Fungal community profiles in agricultural soils of
a long-term field trial under different tillage, fertilization and crop rotation conditions
analyzed by high-throughput ITS-amplicon sequencing. PLoS One 13, e0195345.
Spotts, R. A., Wallis, K. M., Serdani, M., O’Gorman, D. T., Sholberg, P. L. (2009). Real
time polymerase chain reaction for rapid and quantitative determination of
Cystofilobasidium infirmominiatum on the surfaces of apple, pear, and sweet cherry fruit.
Postharvest Biology and Technology 51, 227-231.
Stangroom, J. (2020a). Fisher Exact Test Calculator. Retrieved November 18, 2020, from
https://www.socscistatistics.com/tests/fisher/default2.aspx
Stangroom, J. (2020b). T-Test Calculator for 2 Independent Means. Retrieved November 18,
2020, from https://www.socscistatistics.com/tests/studentttest/default.aspx

76
Stanzani, M., Tumietto, F., Vianelli, N., & Baccarani, M. (2007). Update on the treatment of
disseminated fusariosis: Focus on voriconazole. Therapeutics and Clinical Risk
Management 3, 1165–1173.
Sun, Q. N., Fothergill, A. W., McCarthy, D. I., Rinaldi, M. G., & Graybill, J. R. (2002). In
vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and
fluconazole against 37 clinical isolates of zygomycetes. Antimicrobial Agents and
Chemotherapy 46, 1581–1582.
Tedersoo, L., Bahram, M., Põlme, S., Kõljalg, U., Yorou, N. S., Wijesundera, R., …
Buegger, F. (2014). Global diversity and geography of soil fungi. Science 346, 1078.
Todokoro, D., Yamada, N., Fukuchi, M., & Kishi, S. (2014). Topical voriconazole therapy of
Purpureocillium lilacinum keratitis that occurred in disposable soft contact lens wearers.
International Ophthalmology 34, 1159–1163.
Tuon, F. F., & Costa, S. F. (2008). Rhodotorula infection. A systematic review of 128 cases
from literature. Revista Iberoamericana de Micología 25, 135-40.
Van den Bossche, Willemsens, G., Cools, W., Marichal, P., & Lauwers, W. (1983).
Hypothesis on the molecular basis of the antifungal activity of N-substituted imidazoles
and triazoles. Biochemical Society Transactions 11, 665–667.
Wang, Q. M., Yurkov, A. M., Lumbsch, H. T., Leavitt, S. D., Groenewald, M., Theelen, B.,
Liu, X. Z., Boekhout, T., Bai, F. Y. (2015). Phylogenetic classification of yeasts and
related taxa within Pucciniomycotina. Studies in Mycology 81, 149-189.
Weete, J., & Wise, M. (1987). Effects of triazoles on fungi: V. Response by a naturally tolerant
species, Mucor rouxii. Experimental Mycology 11, 214–222.
White, T., Bruns, T., Lee, S., & Taylor, J. (1990). Amplification and direct sequencing of
fungal ribosomal RNA genes for phylogenetics. PCR protocols: a guide to methods and
applications 18, 315-322.
Wirth, F., & Goldani, L. Z. (2012). Epidemiology of Rhodotorula: an emerging pathogen.
Interdisciplinary Perspectives on Infectious Diseases 2012, 1–7.
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, R., … Wilson, M.
(2018). DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids
Research 46, D1074–D1082.

77
Wong, B., Kiehn, T. E., Edwards, F., Bernard, E. M., Marcove, R. C., Harven, E. D. E., &
Armstrong, D. (1982). Bone infection caused by Debaryomyces hansenii in a normal
host: a case report. Journal of Clinical Microbiology 16, 545–548.
World Health Organization (2019). World Health Organization Model List of Essential
Medicines 21st List, 2019. World Health Organization, Geneva, Switzerland.
Xin, G., Glawe, D., & Doty, S. L. (2009). Characterization of three endophytic, indole-3-acetic
acid- producing yeasts occurring in Populus trees. Mycological Research 113, 973–980.
Yamaguchi, H., Hiratani, T., & Plempel, M. (1983). In vitro studies of a new imidazole
antimycotic, bifonazole, in comparison with clotrimazole and miconazole. ArzneimittelForschung 33, 546-551.
Yurkov, A. M. (2018). Yeasts of the soil–obscure but precious. Yeast 35, 369–378.
Zambounis, A., Ganopoulos, I., Tsaftaris, A., Valasiadis, D., & Madesis, P. (2020).
Metagenomics analysis of fungal communities associated with postharvest diseases in
pear fruits under the effect of management practices. Archives of Microbiology 202,
2391–2400.
Zhao, X. R., Lin, Q., & Brookes, P. C. (2005). Does soil ergosterol concentration provide a
reliable estimate of soil fungal biomass? Soil Biology and Biochemistry 37, 311–317.

78

6

Appendix A

Supplementary Table 1 – Partial ITS Sequences of Yeasts
Top match

Consensus Sequences

CATTAGTGATTGACCTCCGGGTCTTAATAACTATAATCTTCTACCTCTGT
GAACCGTTGGTCTTCGGACCGATTCTTATAACAAACATCTGTGTAATGAA
Bullera alba
CGTAACCTATATTAATCATATAAAACTTTTAACAACGGATCTCTTGGCTC
TCGCATCGATGAAGAACGC
CATTAGTGAATTGCTCTCTGAGCGTTAACTATATCCATCTACACCTGTGA
ACTGTTGATTGACTTCGGTCAGTTACTTTTACAAACATTGTGTAATGAAC
Cutaneotrichosporon terricola GTCATGTTATTATAACAAAAATAACTTTCAACAACGGATCTCTTGGCTCT
CGCATCGATGAAGAACGC
CATTAAAGTATTCTTCGGTGCAGCCAGCGCTTCCACAGCGCGGCAGCCCA
AACCTTACACACTGTGATTAGTTTTTTTACTATTTACTTTGGCTGCGCAA
Cyberlindnera
GTGGCCAAAGGTCTTAAACACAAAGATTTATATCTTTTTTTACAAAATTT
saturnus
AGTCAATGAAGTTTTAATACTATAATCTTCAAAACTTTCAACAACGGATC
TCTTGGTTCTCGCATCGATGAAGAACGCAGC
CTGCGGAAGGATCACTAAAGAATTCGCCCTTCGGGGCTCTCTTTATTCAC
ACACCCCTGTGCACTTTGGCCACCTCTTTGTTGAGGTGTGTCTTTTTAAT
Cystofilobasidium TACCATACCCTATAAACACAAGTTATTGAATGTAAAATCGTTATAAACTA
capitatum
ATATAACTTTCAACAACGGATCTCTTGGTTCTCGCATCGATGAAGAACGC
A
CACTAGAGATTTCGCCCTCCGGGGCTCTCTTTCTTCACACACCCCTGTGC
Cystofilobasidium ACTTTGGCTGCCGCTTCATTGCGGTGGTCTTTTTAATAATTACCATACCC
infirmominiatum ATATACACAAGTCATTGAATGTAAAATCGTTATAAACTAATATAACTTTC
AACAACGGATCTCTTGGTTCTCGCATCGATGAAGAACGCA
CATTACAGTATTCTTTTTGCCAGCGCTTAATTGCGCGGCGAAAAAACCTT
Debaryomyces
ACACACAGTGTTTTTTGTTATTACAAGAACTCTTGCTTTGGTCTGGACTA
nepalensis, D.
GAAATAGTTTGGGCCAGAGGTTTACTGAACTAAACTTCAATATTTATATT
hansenii, D.
GAATTGTTATTTATTTTAATTGTCAATTTGTTGATTAAATTCAAAAAATC
vietnamensis
TTCAAAACTTTCAACAACGGATCTCTTGGTTCTCGCATCGATGAA

Query
length, nt

% query
cover

% ID

169

100

100

168

100

100

231

100

100

189

100

97.9

201

100

100

245

100

100
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Debaryomyces
nepalensis, D.
hansenii, D.
vietnamensis
Diutina
catenulata
Filobasidium
oeirense

Goffeauzyma
gastrica

Hannaella
coprosmae

Hannaella oryzae

Hannaella oryzae

Leucosporidium
scottii
Mrakia arctica,
M. gelida

CATTACAGTATTCTTTTTGCCAGCGCTTAATTGCGCGGCGAAAAAACCTT
ACACACAGTGTTTTTTGTTATTACAAGAACTCTTGCTTTGGTCTGGACTA
GAAATAGTTTGGGCCAGAGGTTTACTAAACTAAACTTCAATATTTATATT
GAATTGTTATTTATTTTAATTGTCAATTTGTTGATTAAATTCAAAAAATC
TTCAAAACTTTCAACAACGGATCTCTTGGTTCTCGCATCGATGAA
CTGCGGAAGGATCATAAAAAACTAATTTACACGCGATTTAAAATTGCTTA
CTTCAATAACCTATTAAACAATCAACCAACTAATACCAAAAACTTCCAAC
AACGGATCTCTTGGTTCTCGCATCGATGAAGAACGCA
CATTAATGAATATAAATCGTACTGTTCACGCAGTATGTGGGGTGGTGACT
TCGGTCCCGCTCATTCATATCCATAACACCTGTGCACTGTTGGATGCTTG
CATCCACTTTTAAACTAAACATTATTGTAACAAATGTAGTCTTATTATAA
CATAATAAAACTTTCAACAACGGATCTCTTGGCTCTCGCATCGAT
CATTAATGAATTCTGAGTAGGCTCTGCCTCTCACCCTTCATATCCATAAA
CACCTGTGCACAGTCGGACCCTTGAGTCTTTCGGGACTCCCGGTGTCTTG
ACGATCTTATCAAACAACAATGTAACCAATGTAATCATTATTATAACATA
ATAAAACTTTTAACAACGGATCTCTTGGCTCTCGCATCGATGAAGAACGC
CATTATTAAATGCGAAGCCATCACTGGCCTAGCTTTATAATCCCTTATTA
CACCTGTGCACCTTATTGTCTTTGGACAATTTTAACAAACATCAGTGTAA
AGAATGTAAACTATTATAATAAATACAACTTTTAACAACGGATCTCTTGG
CTCTCGCATCGATGAAGAACGC
CATTATTAAACGCGAAGCCATCACAGGCCTAGCTTTATAATCCTTATTAC
ACCTGTGCACCTTATTGTCTTCGGACAATCTTTAAAAACAACAGTGTAAC
GAATGTAAACTATTATAAAATAATACAACTTTTAACAACGGATCTCTTGG
CTCTCGCATCGATGAAGAACGC
CTAGCTTTATAATCCTTATTACACCTGTGCACCTTATTGTCTTCGGACAA
TCTTTACAAACAACAGTGTAACGAATGTAAACTATTATAAAATAATACAA
CTTTTAACAACGGATCTCTTGGCTCTCGCATCGATGAAGAACGCA
CATTAGTGAATATTAGCGCATCTACTTGTAGAGCGTGACCTCCACTTTCT
AACTCTGTGCATTTATTGGCGGAAGGACTTGAGCAATCGAGTTTCCTTCT
GCGGCTCATTTTAAAACACTAGTTAAAGTATGTAACGAAATATCGAAACA
AAAAAAACTTTCAACAACGGATCTCTTGGCTTGCGCATCGATGAAGAACG
CAGCAA
CACTAGTGATTAAATCGAGAGCGTCTTCATTGACCTCTCACCCTTCACAT
CCACATACACCTGTGCACCGTTTGACTCTTTTAAAAGACGCAAGTCTGCA

245

100

100

137

100

100

195

100

100

200

100

100

172

100

100

172

100

98.84

145

100

100

202

100

99.5

212

100

99.06
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Mrakia blollopis

Mrakia arctica

FK01_169

Papiliotrema
flavescens

Rhodotorula
babjevae

Rhodotorula
graminis
Rhodotorula
mucilaginosa

AAGAGAGTCATCAATTTTATACATACCCCAGTCTTATGAATGTAACAGTT
TTAATAAACAAAATAAAACTTTTAACAACGGATCTCTTGGTTCTCGCATC
GATGAAGAACGC
CACTAGTGATTAAATCGAGAGCGTCTTCATTGACCTCTCACCCTTCACAT
CCACATACACCTGTGCACCGTTTGGCTCTTATAAAAGACGCAAGTCTGCA
ATGAGAGTCATCAATTTTATACATACCCCAGTCTTATGAATGTAACAGTT
TTAATAAACATAATAAAACTTTTAACAACGGATCTCTTGGTTCTCGCATC
GATGAAGAACGC
CACTAGTGATTAAATCGAGAGCGTCTTCATTGACCTCTCACCCTTCACAT
CCACATACACCTGTGCACCGTTTGGCTCTTTTAAAAGACGTAAGTCTGCA
AAGAGAGTCATCAATTTTATACATACCCCAGTCTTATGAATGTAACAGTT
TTAATAAACAAAATAAAACTTTTAACAACGGATCTCTTGGTTCTCGCATC
GATGAAGAACGC
CATTAGTGAATCTAGCGTGTCTTGCCCTCGAGCAGAGCGCGACCTCTCAC
TCTATACACTGTGCACTTAATAATCGTGGACGAAACTGAAGCCTCTTGGC
CGACGTGACATCTACGTCTTATTTTATACATGAGTAAACGTATGTCATTA
TATTTAAAAAAGAAAAACTTTCAACAACGGATCTCTTGGCTCTCGCATCG
ATGAAGAACGC
CATTATTGATTGGTCGAAAGACCTTATCAGATTCTACCACCTCTGTGAAC
CGTTGACCTCCGGGTTAATAATCAAACATCAGTGTAACGAACGTAAGAGT
ATCTTAATTAAACAAAACTTTTAACAACGGATCTCTTGGCTCTCGCATCG
ATGAAGAACGCA
CATTAGTGAATCTAGGACGTCCAACTTAACTTGGAGTCCGAACTCTCACT
TTCTAACCCTGTGCATCTGTTAATTGGAATAGTAGCTCTTCGGAGTGAAC
CACCATTCACTTATAAAACACAAAGTCTATGAATGTATACAAATTTATAA
CAAAACAAAACTTTCAACAACGGATCTCTTGGCTCTCGCATCGATGAAGA
ACGC
CATTAGTGAATCTAGGACGTCCAACTTAACTTGGAGTCCGAACTCTCACT
TTCTAACCCTGTGCATCTGTTAAATTGGACTAGTAGCTCTTCGGAGTGAA
CCGCCATTCACTTATAAACACAAAGTCTATGAATGTATACAAATTTATAA
CAAAACAAAACTTTCAACAACGGATCTCTTGGCTCTCGCATCGATGAAGA
ACG
CATTAGTGAACATAGGACGTCCAACTTAACTTGGAGTCCGAACTCTCACT
TTCTAACCCTGTGCACTTGTTTGGGATAGTAACTCTCGCAAGAGGGCGAA

212

100

100

212

100

100

211

NA

NA

162

100

100

204

100

100

203

100

100

204

100

100

81

Sampaiozyma
ingeniosa

Schwanniomyces
occidentalis

Solicoccozyma
aeria

Solicoccozyma
terrea

Tausonia
pullulans

Tausonia
pullulans
Vishniacozyma
foliicola

CTCCTATTCACTTATAAACACAAAGTCTATGAATGTATTAAATTTTATAA
CAAAATAAAACTTTCAACAACGGATCTCTTGGCTCTCGCATCGATGAAGA
ACGC
CATTAGTGAATTTAGCGCATCTGCTTTGCAGAGCGTGACCTCCACTTTCT
AACTCTGTGCACTTAATGGCGGAAGAGATGAAATATGCTCTTCTGCGGCT
CATTTTATAACACTAGTTAAAGAATGTAACGAAATATCGAAACAAAAAAA
AACTTTCAACAACGGATCTCTTGGCTCTCGCATCGATGAAGAACGC
CATTACAGTATTCTTTTTGCCAGCGCTTAATTGCGCGGCGAAAAAACCTT
ACACACAGTGTTTTTTGTTATTACAAGAACTTTTGCTTTGGTCTGTCTCT
AGAAATAGAGTTGGGCCAGAGGTTTAACTAAACTTCAATTTTATATTGAA
TTGTTTTTTAATTAATTGTCAATTTGTTGATTAAATTCAAAAAATCTTCA
AAACTTTCAACAACGGATCTCTTGGTTCTCGCATCGATGAAGAACGCA
CATTAGTGAATTAAACATGCTTGGTGTCTTCGCTTCGGCAAGGCCCTTGC
TTAACTCACATCCCAACACCTGTGAACTGTAAGGCGCATGACTAGGTTCG
CCCAAGTCATCGTCTGCCCTTTTTAACAAACAATTAATGTAACAAACGTA
GTCTTATTATAACCTAATAAAACTTTCAACAACGGATCTCTTGGCTCTCG
CATCGATGAAGAACGC
CATTAGTGAATTAAACATGCTTGGTGTCTTCGCTTCGGCAAGGCCCTTGC
TTAAATCACATCCTAACACCTGTGAACTGTAAGACGTATGATGAGGTCTT
TGGCCAAGTCATCGTCTGCCCATTTTTAACAAACAATTAATGTAACAAAC
GTAGTCTTATTATAACCTAATAAAACTTTCAACAACGGATCTCTTGGCTC
TCGCATCGATGAAGAACGCA
CACTAGTGATTAAATCGAGCGTGTCTTCATTGACCGCTCACCCTTCTCAC
CATCCACATACACCTGTGCACTGTTTAGCCTGAGCCGGTTTTCCGGTCCA
GGTTATCATTTCATACAAACTCTAGTCTTATGAATGTAAACGTTTTAATA
ACATAATAAAACTTTCAACAACGGATCTCTTGGTTCTCGCATCGATGAAG
AACGC
CACTAGTGATTAAATCGAGCGTGTCTTCATTGACCGCTCACCCTTCTCAC
CATCCACATACACCTGTGCACTGTTTAGCCTGAGCCGTTTCGGTTCAGGT
TATCATTTCATACAAACTCTAGTCTTATGAATGTAAACGTTTTAATAACA
TAATAAAACTTTCAACAACGGATCTCTTGGTTCTCGCATCGATGAAGAAC
GCA
GATCATTAATGATGCCCTCGAAGTCCTTGGACTGGTAGGGTTTGTGTCGG
TCTCTTCGGAGTCGACCTTATCTCACACACCGTGAACTGTGGCTTCGGCC

196

100

100

248

100

100

220

100

100

220

100

100

205

100

100

203

100

100

189

100

100

82

Vishniacozyma
sp. isolate C220

Vishniacozyma
victoriae

ATTTACACAAACTGTTAGTAATGAATGTAATATCATAACAAACATAAAAC
TTTTAACAACGGATCTCTTGGCTCTCGCATCGATGAAGAACGCA
CATTAATAATGCCCTCTGACTTCGGTCAGCTGGGTTCAAATGAGTGCCTT
CTCTTCGGAGTTGGCCATCCTCACACACCGTGAACTGTGGCTTCGGCCAT
CACAAACTGTTAGTAATGAATGTAATATCATAACAAAAACAAAACTTTTA
ACAACGGATCTCTTGGCTCTCGCATCGATGAAGAACGCA
CATTAATAGTGCTCATTGACGCAAGTCAGTGAGTTAGATCTGCTCTCTTC
GCAAGAAGAGGGTTTCCATACACACCGTGAACTGTGGCTTCGGCCATCAC
AAACTGTTAGTAATGAATGTAATATCATAACAAAAACAAAACTTTTAACA
ACGGATCTCTTGGCTCTCGCATCGATGAAGAACGCA

194

100

99.48

186

100

97.31

83
Supplementary Table 2 – Partial ITS Sequences of Filamentous Fungi
Top match

Consensus sequence

ATTACTGAGTGTAAAAACTCCCAACCCTTTGTGAACATACCTCTGTTGCT
TCGGCGGATGCGCCCCGGGCGCGCCTTCTAGGAGGCGTGCCCCGGAACCA
Acremonium sp. GGCGCCCGCCGGGGGACCTACAAACTCTTGTATTCCTAGCGGATCTCTGA
MJ35
GTGTGATTTAAACAAATCAAATCAAAACTTTCAACAACGGATCTCTTGGC
TCTAGCATCGATGAAGAACGC
ATTACAGAGTTGCAAAACTCCCCAAACCATTGTGAACCTTACCTTCAACC
GTTGCTTCGGCGGGCGGGCCACAGCGCCCCCCGGGCCCCCCCAGCGGGGC
Acrophialophora GCCCGCCGGAGGATACCCAAACTCTTGATACTTTATGGCCTCTCTGAGTC
levis
TTCTGTACTGAATAAGTCAAAACTTTCAACAACGGATCTCTTGGTTCTGG
CATCGATGAAGAACGCA
CATTAAATAAAACTTGAGGGGAAACTGGGCTTACGGGCTTGGTTTTTCTC
TTATTTTTTACCGTGAACTGTCTTATAGCATGGCGCTAGTAGAGATGCCT
GAGCCGCCATACGGGGTAGGCGGCACAGGATGATTTTAATCGAAGCCATG
Actinomucor
GTCAAGCCGACTTTTTTTCAGCTTGGTACCCCAAAAATTAATTATTCTAC
elegan
CAAATGAATTCAGTATTAATATTGTAACATGGGCTCGCTGAAAGGTGGCC
TATAAAACAACTTTTAACAACGGATCTCTTGGTTCTCGCATCGATGAAGA
ACGCA
CATTAAATAAAACTTGAGGGGAAACTGGGCCTACGGGTTTGGTTTTTCCC
TTATTTTTTACCGTGAACTGTCTTATAGCATGGCGCTAGTAGAGATGCCT
GAGCCACCATACGGGGTAGGCGGCACAGGATGATTTTAATCGAAGCCATG
Actinomucor
GTCAAGCCGACTTTTTTTCAGCTTGGTACCCCAAAAATTAATTATTCTAC
elegans
CAAATGAATTCAGTATTAATATTGTAACATGGGCTCGCTGAAAGGTGGCC
TATAAAACAACTTTTAACAACGGATCTCTTGGTTCTCGCATCGATGAAGA
ACGCA
TACCGAGTTTACAAACTCCCAAACCCTTTGTGAACCTTACCATATTGTTG
CTTCGGCGGGACCGCCCCGGCGCCTTCGGGCCCGGAACCAGGCGCCCGCC
Albifimbria
GGAGGCCCCAAACTCTTATGTCTTTAGTGGTTTTCTCCTCTGAGTGACAC
verrucaria, viridis ATAAACAAATAAATAAAAACTTTCAACAACGGATCTCTTGGTTCTGGCAT
CGATGAAGAACGCA

Query
length, nt

% query
cover

% ID

221

100

100

217

100

100

305

99

100

305

99

100

214

100

100
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Aspergillus
fumigatus,
fumigatiaffinis

Aspergillus
[multiple]

Cladosporium
[multiple]

Clonostachys
rosea (A)

Clonostachys
rosea (B)

Fusarium
oxysporium
Fusarium
incarnatumequiseti

CATTACCGAGTGAGGGCCCTCTGGGTCCAACCTCCCACCCGTGTCTATCG
TACCTTGTTGCTTCGGCGGGCCCGCCGTTTCGACGGCCGCCGGGGAGGCC
CTGCGCCCCCGGGCCCGCGCCCGCCGAAGACCCCAACATGAACGCTGTTC
TGAAAGTATGCAGTCTGAGTTGATTATCGTAATCAGTTAAAACTTTCAAC
AACGGATCTCTTGGTTCCGGCATCGATGAAGAACGCA
TACCGAGTGAGGACCTAACCGGTCCAACCTCCCACCCGTGTCTATCGTAC
CTTGTTGCTTCGGCGGGCCCGCCATTCGTGGCCGCCGGGGGGCATCTCGC
CCCCGGGCCCGCGCCCGCCGGAGACACCAACACGAACACTGTCTGAAGGT
TGCAGTCTGAGTCGATTTATTTAATCGTTAAAACTTTCAACAACGGATCT
CTTGGTTCCGGCATCGATGAAGAACGCAGCA
CATTACAAGTGACCCCGGTCTAACCACCgggatgTTcATAACCCTTTGTT
GTCCGACTCTGTTGCCTCCGGGGCGACCCTGCCTTCGGGCGGGGGCTCCG
GGTGGACACTTCAAACTCTTGCGTAACTTTGCAGTCTGAGTAAACTTAAT
TAATAAATTAAAACTTTTAACAACGGATCTCTTGGTTCTGGCATCGATGA
A
CATTACCGAGTTTACAACTCCCAAACCCATGTGAACATACCTACTGTTGC
TTCGGCGGGATTGCCCCGGGCGCCTCGTGTGCCCCGGATCAGGCGCCCGC
CTAGGAAACTCAACTCTTGTTTTATTTTGGAATCTTCTGAGTAGTTTTTA
CAAATAAATAAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATG
AAGAACGCA
CATTACCGAGTTTACAACTCCCAAACCCATGTGAACATACCTACTGTTGC
TTCGGCGGGATTGCCCCGGGCGCCTCGTGTGCCCCGGATCAGGCGCCCGC
CTAGGAAACTTAATTCTTGTTTTATTTTGGAATCTTCTGAGTAGTTTTTA
CAAATAAATAAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATG
AAGAACGCA
CATTACCGAGTTTACAACTCCCAAACCCCTGTGAACATACCACTTGTTGC
CTCGGCGGATCAGCCCGCTCCCGGTAAAACGGGACGGCCCGCCAGAGGAC
CCCTAAACTCTGTTTCTATATGTAACTTCTGAGTAAAACCATAAATAAAT
CAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACGCA
CATTACCGAGTTTACAACTCCCAAACCCCTGTGAACATACCTATACGTTG
CCTCGGCGGATCAGCCCGCGCCCTGTAAAAAGGGACGGCCCGCCCGAGGA
CCCTAAACTCTGTTTTTAGTGGAACTTCTGANTAAAACAAACAAATAAAT
CAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATC

237

100

100

231

99

100

201

100

100

209

100

100

209

100

100

200

100

100

187

100

100

85

Metarhizium
robertsii

Metarhizium
marquandii

Mortierella
alpina (A)

Mortierella
alpina (B)

Mortierella
alpina (C)

Mortierella
gamsii

Mortierella
hyalina

TACCGAGTTATCCAACTCCCAACCCCTGTGAATTATACCTTTAATTGTTG
CTTCGGCGGGACTTCGCGCCCGCCGGGGACCCAAACCTTCTGAATTTTTT
AATAAGTATCTTCTGAGTGGTTAAAAAAATGAATCAAAACTTTCAACAAC
GGATCTCTTGGTTCTGGCATCGATGA
TACCGAGTTTTCAACTCCCAAACCCACTGTGAACATATACCATTTGTTTA
TTCGTTGCCTCGGCGGGTTCTACTCCCTGGAGACAGGGGGCCAGCCCCCG
CCGGTGTAACACCCAAAACCCTGAATGTGTACCCGTTACACGGCAGTATT
ACTCTGAGTCACATCATTTTAAATGAATCAAAACTTTCAACAACGGATCT
CTTGGTTCTGGCATCGATGAAGAACGCAGCA
CATTCATAATCAAGTGTTTTTATGGCACTTTCAAAAATCCATATCCCCTT
GTGTGCAATGTCATCTCTCTGGGGGCTGCCGGCTGTCAAAAGCCGTGTGG
TCACCTTTGGGATTTATATCTACTCAGAACTTTAGTGATTTTGTCTGAAA
CATATTATGAATACTTAATTCAAAATACAACTTTCAACAACGGATCTCTT
GGCTCTCGCATCGATGAAGAACGCA
CATTCATAATCAAGTGTTTTTATGGCACTTTCAAAAATCCATATCCACCT
TGTGTGCAATGTCATCTCACTGGGGGCCACCGGCTGTCAAAAGCCGTCTG
GTCACCTTTGGGATTTATATCTACTCAGAACTTTAGTGATTTTGTCTGAA
ACATATTATGAATACTTAATTCAAAATACAACTTTCAACAACGGATCTCT
TGGCTCTCGCATCGATGAAGAACGCA
CATTCATAATCAAGTGTTTTTATGGCACTTTCAAAAATCCATATCCACCT
TGTGTGCAATGTCATCTCTCTGGGGGCTGCCGGCTGTCAAAAGCCGTGTG
GTCACCTTTGGGATTTATATCTACTCAGAACTTTAGTGATTTTGTCTGAA
ACATATTATGAATACTTAATTCAAAATACAACTTTCAACAACGGATCTCT
TGGCTCTCGCATCGATGA
CATTCATAATAAGTGTTTTATGGCACTTTTTAAATCCATATCCACCTTGT
GTGCAATGTCAGTTGTTCTCTTTTTTGAGAATGACCAAACATCAACTTAT
TCTTTAACTCTTTGTCTGAAAAATATTATGAATAAAATAATTCAAAATAC
AACTTTCAACAACGGATCTCTTGGCTCTCGCATCGATGAAGAACGCA
CATTCATAATAAGTGTTTTATGGCACTTTTTTAAATCCATATCCACCTTG
TGTGCAATGTCAGGGTTGGTTTCTCTCTTTTGAGAGATCAACCCCAAACA
TCAACTCTATCTTAACTCTTTGTCTGAAAAATATTATGAATAAAACAATT
CAAAATACAACTTTCAACAACGGATCTCTTGGCTCTCGCATCGATGAAGA
ACGCA

176

100

100

231

100

100

225

100

100

226

100

100

218

100

100

197

100

100

205

100

100

86

Mucor
circinelloides

Neosartorya
udagawae

Penicillium
oxalicum (A)

Penicillium
oxalicum (B)

Penicillium
novae-zeelandiae

Plectosphaerella
cucumerina
Purpureocillium
lilacinum

CATTAAATAATCAATAATTTTGGCTTGTCCATTATTATCTATTTACTGTG
AACTGTATTATTACTTGACGCTTGAGGGATGCTCCACTGCTATAAGGATA
GGCGATGGAGATGCTAACCGAGTCATAATCAAGCTTAGGCTTGGTATCCT
ATTATTATTTACCAAAAGAATTCAGAATTAATATTGTAACATAGACCTAA
AAAATCTATAAAACAACTTTTAACAACGGATCTCTTGGTTCTCGCATCGA
TGAA
CATTACCGAGTGAGGGCCCTCTGGGTCCAACCTCCCACCCGTGTCTATCG
TACCTTGTTGCTTCGGCGGGCCCGCCGTTTCGACGGCCGCCGGGGAGGCC
TCGCGCCCCCGGGCCCGCGCCCGCCGAAGACCCCAACATGAACTCTGTTC
TGGAAGTATGCAGTCTGAGTTGATTATCATAATCAGTTAAAACTTTCAAC
AACGGATCTCTTGGTTCCGGCATCGATGAAGAACGCA
TTACCGAGTGAGGGCCCTCTGGGTCCAACCTCCCACCCGTGTTTATCGTA
CCTTGTTGCTTCGGCGGGCCCGCCTCACGGCCGCCGGGGGGCATCTGCCC
CCGGGCCCGCGCCCGCCGAAGACACACAAACGAACTCTTGTCTGAAGATT
GCAGTCTGAGTACTTGACTAAATCAGTTAAAACTTTCAACAACGGATCTC
TTGGTTCCGGCATCGATGANGAACGCAGC
CATTACCGAGTGAGGGCCCTCTGGGTCCAACCTCCCACCCGTGTTTATCG
TACCTTGTTGCTTCGGCGGGCCCGCCTCACGGCCGCCGGGGGGCATCCGC
CCCCGGGCCCGCGCCCGCCGAAGACACACAAACGAACTCTTGTCTGAAGA
TTGCAGTCTGAGTACTTGACTAAATCAGTTAAAACTTTCAACAACGGATC
TCTTGGTTCCGGCATCGATGAAGAACGCA
CATTACCGAGCGAGGATTCTCTGAATCCAACCTCCCACCCGTGTTTATTG
TACCTTGTTGCTTCGGCGGGCCCGCCTCACGGCCGCCGGGGGGCATCTGC
CCCCGGGCCCGCGCCCGCCGAAGACACCTTGAACTCTGTATGAAAATTGC
AGTCTGAGTCTAAATATAAATTATTTAAAACTTTCAACAACGGATCTCTT
GGTTCCGGCATCGATGAAGAACGCA
CATTACTGAGTACTACACTCTCTACCCTTTGTGAACTATTATACCTGTTG
CTTCGGCGGCGCCCGCGAGGGTGCCCGCCGGTCTCATCAGAATCTCTGTT
TTCGAACCCGACGATACTTCTGAGTGTTCTTAGCGAACTGTCAAAACTTT
TAACAACGGATCTCTTGGCTCCAGCATCGATGAAGAACGCA
CATTACCGAGTTATACAACTCCCAAACCCACTGTGAACCTTACCTCAGTT
GCCTCGGCGGGAACGCCCCGGCCGCCTGCCCCCGCGCCGGCGCCGGACCC
AGGCGCCCGCCGCAGGGACCCCAAACTCTCTTGCATTACGCCCAGCGGGC

254

100

100

237

100

100

229

99

100

229

100

100

225

100

100

191

100

100

241

100

100

87

Rhizomucor
variabilis

GGAATTTCTTCTCTGAGTTGCACAAGCAAAAACAAATGAATCAAAACTTT
CAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACGCA
CATTAAATAATCAATAATTTTGGCTTGTCCATTATTATCTATTTACTGTG
AACTGTATTATTACTTGACGCTTGAGGGATGCTCCACTGCTATAAGGATA
GGCGGTGGGGATGTTAACCGAGTCATAGTCAAGCTTAGGCTTGGTATCCT
ATTATTATTTACCAAAAGAATTCAGAATTAATATTGTAACATAGACCTAA
AAAATCTATAAAACAACTTTTAACAACGGATCTCTTGGTTCTCGCATCGA
TGAAGAACGCA

261

100

100

88

Supplementary Figure 1 – Examples of Disk Diffusion Assay Interpretations
The shown Cyberlindnera saturnus isolate (left) was determined to be sensitive to clotrimazole
and miconazole (top rows), as well as itraconazole (bottom right), but resistant to fluconazole
(bottom left), and weakly susceptible to voriconazole (bottom centre). The zone of inhibition
measurement for voriconazole, which showed trailing growth, was determined by measuring from
the edges of the apparent start of the trailing growth and is illustrated here by the red bar. Likewise,
the shown Debaryomyces hansenii isolate (middle) was determined to be resistant to fluconazole
(bottom left) due to the normal-sized colonies within a zone of 70 mm from the disk. Also, the
ZOI against clotrimazole and itraconazole for the shown Sampaiozyma ingeniosa isolate (right)
was determined to be between 70 and 150 mm due to small zones of inhibition reaching just below
150 mm to each disk.
Supplementary Table 3 – Contingency Tables used for Fisher Exact Tests, Analysis of
Drug Cross-resistance
3.1 - Number of sensitive
and resistant isolates to
clotrimazole, voriconazole,
or both drugs*
VRCS

VRCR

CTZS

81

46

CTZR

1

7

3.4 - Number of sensitive
and resistant isolates to
voriconazole, itraconazole,
or both drugs*
ITRS

ITRR

VRCS

52

1

VRCR

39

14

3.2 - Number of sensitive and
resistant isolates to
miconazole, voriconazole, or
both drugs*
VRCS

VRCR

MCZS

81

30

MCZR

1

22

3.5 - Number of sensitive and
resistant isolates to
propiconazole, itraconazole, or
both drugs*
PROS

PROR

VRCS

73

0

VRCR

26

7

3.3 - Number of sensitive
and resistant isolates to
fluconazole, voriconazole, or
both drugs*
VRCS

VRCR

FCZS

46

0

FCZR

36

52

3.6 - Number of sensitive
and resistant isolates to
itraconazole, fluconazole, or
both drugs
ITRS

ITRR

FCZS

46

0

FCZR

74

14

89
3.7 - Number of sensitive
and resistant isolates to
miconazole, fluconazole,
or both drugs
FCZS
FCZR

3.8 Number of sensitive and
resistant isolates to
miconazole, itraconazole, or
both drugs
ITRS
ITRR

MCZS

41

72

MCZS

110

5

CTZS

121

20

MCZR

0

47

MCZR

13

10

CTZR

5

3

3.10 - Number of sensitive
and resistant isolates to
clotrimazole, fluconazole,
or both drugs*
FCZS
FCZR
CTZS
R

CTZ

46
0

80
8

3.13 - Number of sensitive
and resistant isolates to
propiconazole, miconazole,
or both drugs*
PROS
PROR

3.11 - Number of sensitive and
resistant isolates to
clotrimazole, itraconazole, or
both drugs*
ITRS
ITRR
CTZS
R

CTZ

158
6

12
2

3.14 - Number of sensitive and
resistant isolates to
propiconazole, voriconazole,
or both drugs
PROS
PROR

3.9 - Number of sensitive
and resistant isolates to
clotrimazole, miconazole, or
both drugs
MCZS
MCZR

3.12 - Number of sensitive
and resistant isolates to
propiconazole, clotrimazole,
or both drugs*
PROS
PROR
CTZS
R

CTZ

97

3

1

4

3.15 - Number of sensitive
and resistant isolates to
propiconazole, fluconazole,
or both drugs
PROS
PROR

MCZS

88

1

ITRS

79

6

FCZS

9

0

MCZR

8

6

ITRR

7

1

FCZR

77

7

90
Supplementary Table 4 – Contingency Tables used for Fisher Exact Tests, Analysis of
Isolates Highly Susceptible to Miconazole
4.1 - Number of highly
susceptible isolates to
miconazole isolated from
the control versus the low
treatment plots
ZOI < ZOI >=
250
250
mm
mm
From
control
39
8
plots
From
low
51
2
plots

4.2 - Number of highly
susceptible isolates to
miconazole isolated from
the control versus the high
treatment plots
ZOI < ZOI >=
250
250
mm
mm
From
control
39
8
plots
From
high
42
2
plots
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